|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions increases expression decreases expression |
ISO EXP |
[Cyclophosphamide results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 mRNA; ABCB1 protein affects the susceptibility to [Cyclophosphamide co-treated with Methotrexate co-treated with Fluorouracil]; ABCB1 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide]; NR1I2 protein promotes the reaction [Cyclophosphamide results in increased expression of ABCB1 protein] Cyclophosphamide results in decreased expression of ABCB1 mRNA; Cyclophosphamide results in decreased expression of ABCB1A mRNA |
CTD |
PMID:12576456 PMID:20041327 PMID:20623750 PMID:30563925 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions decreases response to substance |
ISO |
ABCC1 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide] ABCC1 protein results in decreased susceptibility to Cyclophosphamide |
CTD |
PMID:11778547 PMID:12576456 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
ABCG2 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide] |
CTD |
PMID:12576456 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abhd3 |
abhydrolase domain containing 3, phospholipase |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ABHD3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr18:1,723,203...1,778,488
Ensembl chr18:1,720,718...1,803,428
|
|
G |
Abi2 |
abl-interactor 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of ABI2 mRNA |
CTD |
PMID:27466211 |
|
NCBI chr 9:61,827,186...61,905,703
Ensembl chr 9:61,827,139...61,905,699
|
|
G |
Ace |
angiotensin I converting enzyme |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of ACE mRNA |
CTD |
PMID:27281708 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ACE2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions increases expression |
EXP |
Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of ACHE protein] |
CTD |
PMID:37419146 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Ackr3 |
atypical chemokine receptor 3 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of ACKR3 mRNA |
CTD |
PMID:20032115 |
|
NCBI chr 9:90,799,682...90,811,246
Ensembl chr 9:90,799,686...90,811,237
|
|
G |
Acod1 |
aconitate decarboxylase 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ACOD1 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr15:79,871,819...79,881,101
Ensembl chr15:79,871,827...79,880,529
|
|
G |
Acsl4 |
acyl-CoA synthetase long-chain family member 4 |
increases expression multiple interactions |
ISO |
Cyclophosphamide results in increased expression of ACSL4 protein Dexrazoxane inhibits the reaction [Cyclophosphamide results in increased expression of ACSL4 protein] |
CTD |
PMID:37690746 |
|
NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427
|
|
G |
Actb |
actin, beta |
decreases expression affects expression |
ISO EXP |
Cyclophosphamide results in decreased expression of ACTB mRNA Cyclophosphamide affects the expression of ACTB mRNA |
CTD |
PMID:10859244 PMID:12167460 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Adam24 |
ADAM metallopeptidase domain 24 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of ADAM24 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr16:51,578,278...51,584,265
Ensembl chr16:51,578,277...51,584,312
|
|
G |
Adamts9 |
ADAM metallopeptidase with thrombospondin type 1 motif, 9 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of ADAMTS9 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 4:125,290,633...125,462,988
Ensembl chr 4:125,291,490...125,462,929
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
affects expression increases expression |
EXP |
Cyclophosphamide affects the expression of ADCYAP1 mRNA Cyclophosphamide results in increased expression of ADCYAP1 protein |
CTD |
PMID:9776515 PMID:10754506 PMID:18563302 |
|
NCBI chr 9:113,102,632...113,122,500
Ensembl chr 9:113,103,718...113,109,773
|
|
G |
Adcyap1r1 |
ADCYAP receptor type I |
affects expression |
EXP |
Cyclophosphamide affects the expression of ADCYAP1R1 mRNA |
CTD |
PMID:18563302 |
|
NCBI chr 4:84,593,558...84,642,700
Ensembl chr 4:84,593,892...84,642,700
|
|
G |
Adm |
adrenomedullin |
affects response to substance |
ISO |
ADM protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Afp |
alpha-fetoprotein |
affects expression |
ISO |
Cyclophosphamide affects the expression of AFP protein |
CTD |
PMID:6177358 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Agl |
amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase |
affects response to substance |
ISO |
AGL protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 2:204,705,053...204,760,966
Ensembl chr 2:204,705,053...204,760,828
|
|
G |
Akap8 |
A-kinase anchoring protein 8 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of AKAP8 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 7:11,316,224...11,332,523
Ensembl chr 7:11,316,228...11,332,399
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases expression |
EXP |
Cyclophosphamide results in increased phosphorylation of and results in increased activity of AKT1 protein; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of AKT1 protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of AKT1 protein] |
CTD |
PMID:19996110 PMID:25446862 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alad |
aminolevulinate dehydratase |
multiple interactions |
ISO |
[Cyclophosphamide co-treated with Carmustine co-treated with Etoposide] results in decreased activity of ALAD protein |
CTD |
PMID:19162187 |
|
NCBI chr 5:75,961,993...75,972,334
Ensembl chr 5:75,961,993...75,972,474
|
|
G |
Alcam |
activated leukocyte cell adhesion molecule |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ALCAM mRNA |
CTD |
PMID:21041162 |
|
NCBI chr11:48,336,123...48,536,296
Ensembl chr11:48,336,169...48,537,954
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
affects response to substance decreases response to substance increases expression |
ISO |
ALDH1A1 protein affects the susceptibility to Cyclophosphamide ALDH1A1 protein results in decreased susceptibility to Cyclophosphamide Cyclophosphamide results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:12513786 PMID:17403535 PMID:18854779 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ALDH2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
affects response to substance |
ISO |
ALDH3A1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:18854779 |
|
NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681
|
|
G |
Alox5ap |
arachidonate 5-lipoxygenase activating protein |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ALOX5AP mRNA |
CTD |
PMID:17403535 |
|
NCBI chr12:5,748,941...5,772,986
Ensembl chr12:5,748,944...5,772,986
|
|
G |
Alyref |
Aly/REF export factor |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ALYREF mRNA |
CTD |
PMID:21041162 |
|
NCBI chr10:105,871,424...105,875,076
Ensembl chr10:105,871,306...105,875,069
|
|
G |
Amfr |
autocrine motility factor receptor |
multiple interactions |
ISO |
AMFR mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr19:10,996,705...11,032,260
Ensembl chr19:10,996,099...11,032,247
|
|
G |
Amh |
anti-Mullerian hormone |
decreases expression multiple interactions |
EXP |
Cyclophosphamide results in decreased expression of AMH protein Cilostazol inhibits the reaction [Cyclophosphamide results in decreased expression of AMH protein]; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of AMH protein] |
CTD |
PMID:32456565 PMID:36154502 |
|
NCBI chr 7:8,906,776...8,909,192
Ensembl chr 7:8,906,836...8,909,282
|
|
G |
Angpt1 |
angiopoietin 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ANGPT1 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067
|
|
G |
Ankrd40 |
ankyrin repeat domain 40 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of TMPRSS2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr10:79,282,075...79,295,322
Ensembl chr10:79,282,075...79,295,320
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of APAF1 mRNA |
CTD |
PMID:29445054 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of APEX1 mRNA; Cyclophosphamide results in increased expression of APEX1 protein |
CTD |
PMID:11599041 PMID:15928459 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Apob |
apolipoprotein B |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of APOB mRNA |
CTD |
PMID:18246545 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoe |
apolipoprotein E |
decreases expression increases expression |
ISO |
Cyclophosphamide results in decreased expression of APOE mRNA Cyclophosphamide results in increased expression of APOE mRNA |
CTD |
PMID:15331540 PMID:21041162 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Apoh |
apolipoprotein H |
increases expression |
EXP |
Cyclophosphamide results in increased expression of APOH protein |
CTD |
PMID:15928459 |
|
NCBI chr10:93,342,435...93,356,334
Ensembl chr10:93,310,977...93,356,329
|
|
G |
Arg1 |
arginase 1 |
increases expression affects expression decreases expression |
ISO EXP |
Cyclophosphamide results in increased expression of ARG1 mRNA Cyclophosphamide affects the expression of ARG1 mRNA Cyclophosphamide results in decreased expression of ARG1 mRNA |
CTD |
PMID:18246545 PMID:21068404 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Arhgdib |
Rho GDP dissociation inhibitor beta |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ARHGDIB mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 4:169,822,951...169,841,884
Ensembl chr 4:169,822,952...169,841,658
|
|
G |
Arhgef26 |
Rho guanine nucleotide exchange factor 26 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ARHGEF26 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 2:146,740,336...146,850,918
Ensembl chr 2:146,739,631...146,850,819
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of ASNS mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of ASS1 protein |
CTD |
PMID:15928459 |
|
NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
|
|
G |
Atf2 |
activating transcription factor 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of ATF2 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236
|
|
G |
Atf5 |
activating transcription factor 5 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ATF5 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707
|
|
G |
Atg3 |
autophagy related 3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ATG3 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr11:55,624,914...55,653,249
Ensembl chr11:55,624,917...55,653,224
|
|
G |
Atg5 |
autophagy related 5 |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of ATG5 protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of ATG5 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of ATG5 protein] |
CTD |
PMID:32151603 |
|
NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Atg7 |
autophagy related 7 |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of ATG7 protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of ATG7 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of ATG7 protein] |
CTD |
PMID:32151603 |
|
NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593
|
|
G |
Aurkb |
aurora kinase B |
increases expression |
EXP |
Cyclophosphamide results in increased expression of AURKB mRNA |
CTD |
PMID:11599041 |
|
NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
|
|
G |
Axl |
Axl receptor tyrosine kinase |
increases expression |
ISO |
Cyclophosphamide results in increased expression of AXL mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265
|
|
G |
B3galnt2 |
beta-1,3-N-acetylgalactosaminyltransferase 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of B3GALNT2 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr17:51,334,921...51,377,469
Ensembl chr17:51,334,921...51,377,469
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression multiple interactions |
EXP ISO |
Cyclophosphamide results in increased expression of BAD mRNA Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of BAD protein] |
CTD |
PMID:11599041 PMID:29753871 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bag1 |
BAG cochaperone 1 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of BAG1 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 5:56,068,494...56,081,075
Ensembl chr 5:56,068,494...56,081,075
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
EXP ISO |
Cyclophosphamide results in increased expression of BAX mRNA; Cyclophosphamide results in increased expression of BAX protein [Rutin co-treated with Chitosan] inhibits the reaction [Cyclophosphamide results in increased expression of BAX mRNA]; herbacetin inhibits the reaction [Cyclophosphamide results in increased expression of BAX mRNA]; Melatonin inhibits the reaction [Cyclophosphamide results in increased expression of BAX protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased expression of BAX mRNA]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased expression of BAX protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of BAX protein] Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of BAX protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of BAX protein] |
CTD |
PMID:25446862 PMID:29753871 PMID:30506662 PMID:32197949 PMID:36154502 PMID:36198566 PMID:38211767 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression multiple interactions |
EXP |
Cyclophosphamide results in increased expression of BBC3 mRNA sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased expression of BBC3 mRNA]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of BBC3 mRNA] |
CTD |
PMID:32197949 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bbs4 |
Bardet-Biedl syndrome 4 |
multiple interactions |
ISO |
BBS4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 8:59,731,912...59,765,408
Ensembl chr 8:59,731,912...59,765,607
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions decreases activity |
ISO |
[Melphalan co-treated with Thiotepa co-treated with Cyclophosphamide] results in decreased expression of BCHE protein Cyclophosphamide results in decreased activity of BCHE protein |
CTD |
PMID:4672170 PMID:4959505 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression decreases expression |
ISO EXP |
[Cladribine co-treated with Cyclophosphamide co-treated with Mitoxantrone] results in decreased expression of BCL2 protein; [Cladribine co-treated with Cyclophosphamide] results in decreased expression of BCL2 protein; [Doxorubicin co-treated with Cyclophosphamide] affects the expression of BCL2 mRNA; [Doxorubicin co-treated with Dexamethasone co-treated with Vincristine co-treated with Cytarabine co-treated with Mercaptopurine co-treated with Methotrexate co-treated with Cyclophosphamide co-treated with Enzymes and Coenzymes] results in increased expression of BCL2 protein; BCL2 protein inhibits the reaction [Cyclophosphamide results in increased activity of CASP3 protein]; BCL2 protein inhibits the reaction [Cyclophosphamide results in increased activity of CASP9 protein]; Cyclophosphamide promotes the reaction [SGI-1027 results in decreased expression of BCL2 protein]; PAX5 protein affects the reaction [Cyclophosphamide results in decreased expression of BCL2 protein]; SGI-1027 promotes the reaction [Cyclophosphamide results in decreased expression of BCL2 protein]; Valproic Acid inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 protein] Cyclophosphamide results in increased expression of BCL2 mRNA Cyclophosphamide results in decreased expression of BCL2 mRNA; Cyclophosphamide results in decreased expression of BCL2 protein [Rutin co-treated with Chitosan] inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 mRNA]; herbacetin inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 mRNA]; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 mRNA]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 protein] Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 protein] |
CTD |
PMID:11723234 PMID:14503796 PMID:15582267 PMID:16322899 PMID:21182165 PMID:25446862 PMID:29753871 PMID:30506662 PMID:32197949 PMID:33737021 PMID:34658283 PMID:36154502 PMID:36198566 PMID:38211767 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
increases expression decreases expression |
EXP ISO |
Cyclophosphamide results in increased expression of BCL2L1 mRNA Cyclophosphamide results in decreased expression of BCL2L1 mRNA |
CTD |
PMID:11599041 PMID:33737021 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
increases expression multiple interactions |
EXP |
Cyclophosphamide results in increased expression of BCL2L11 mRNA sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased expression of BCL2L11 mRNA]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of BCL2L11 mRNA] |
CTD |
PMID:32197949 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bcl2l2 |
Bcl2-like 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of BCL2L2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr15:28,346,449...28,361,627
Ensembl chr15:28,356,807...28,361,624
|
|
G |
Bcl6 |
BCL6, transcription repressor |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of BCL6 mRNA Cyclophosphamide metabolite results in decreased expression of BCL6 mRNA |
CTD |
PMID:21041162 PMID:24356939 |
|
NCBI chr11:76,854,090...76,877,389
Ensembl chr11:76,854,090...76,877,389
|
|
G |
Bdh1 |
3-hydroxybutyrate dehydrogenase 1 |
affects response to substance |
ISO |
BDH1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr11:69,302,534...69,343,173
Ensembl chr11:69,302,534...69,337,671
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of BDKRB1 mRNA |
CTD |
PMID:10498854 PMID:15576455 |
|
NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
affects expression |
EXP |
Cyclophosphamide affects the expression of BDKRB2 mRNA |
CTD |
PMID:15576455 |
|
NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression multiple interactions |
EXP |
Cyclophosphamide results in increased expression of BDNF mRNA; Cyclophosphamide results in increased expression of BDNF protein O-1602 compound inhibits the reaction [Cyclophosphamide results in increased expression of BDNF protein] |
CTD |
PMID:10683293 PMID:32615180 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Becn1 |
beclin 1 |
multiple interactions decreases expression increases expression |
ISO |
BECN1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] Cyclophosphamide results in decreased expression of BECN1 protein asperuloside promotes the reaction [Cyclophosphamide results in increased expression of BECN1 protein]; CSF2 protein promotes the reaction [Cyclophosphamide results in increased expression of BECN1 protein]; dorsomorphin inhibits the reaction [asperuloside promotes the reaction [Cyclophosphamide results in increased expression of BECN1 protein]]; dorsomorphin inhibits the reaction [Cyclophosphamide results in increased expression of BECN1 protein]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of BECN1 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of BECN1 protein] |
CTD |
PMID:16896004 PMID:32151603 PMID:38348709 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bik |
BCL2-interacting killer |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of BIK mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 7:114,672,277...114,691,296
Ensembl chr 7:114,672,277...114,691,296
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of BIRC3 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Blvrb |
biliverdin reductase B |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of BLVRB protein |
CTD |
PMID:9006340 |
|
NCBI chr 1:82,738,646...82,756,312
Ensembl chr 1:82,738,695...82,770,375
|
|
G |
Bpi |
bactericidal/permeability-increasing protein |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of BPI mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 3:146,909,626...146,936,487
Ensembl chr 3:146,909,629...146,936,221
|
|
G |
Brpf1 |
bromodomain and PHD finger containing, 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of BRPF1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 4:146,456,325...146,472,781
Ensembl chr 4:146,456,318...146,472,649
|
|
G |
Bscl2 |
BSCL2 lipid droplet biogenesis associated, seipin |
increases expression |
ISO |
Cyclophosphamide results in increased expression of BSCL2 mRNA |
CTD |
PMID:22003191 |
|
NCBI chr 1:205,731,828...205,743,430
Ensembl chr 1:205,733,872...205,743,421
|
|
G |
Bsg |
basigin |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of BSG mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 7:9,993,170...10,000,387
Ensembl chr 7:9,993,170...10,000,387
|
|
G |
Btg1 |
BTG anti-proliferation factor 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of BTG1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 7:31,341,391...31,343,649
Ensembl chr 7:31,341,027...31,343,649
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of BTG2 mRNA |
CTD |
PMID:29445054 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
Btg3 |
BTG anti-proliferation factor 3 |
multiple interactions |
ISO |
BTG3 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr11:17,030,156...17,046,069
Ensembl chr11:17,030,160...17,046,170
|
|
G |
Bub3 |
BUB3 mitotic checkpoint protein |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of BUB3 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 1:186,330,358...186,340,969
Ensembl chr 1:186,327,931...186,395,036
|
|
G |
C1qa |
complement C1q A chain |
increases expression |
ISO |
Cyclophosphamide results in increased expression of C1QA mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 5:149,133,635...149,136,482
Ensembl chr 5:149,133,636...149,136,534
|
|
G |
C3 |
complement C3 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of C3 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
Cabp1 |
calcium binding protein 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CABP1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr12:41,385,234...41,448,930
Ensembl chr12:41,378,897...41,448,927
|
|
G |
Cabp2 |
calcium binding protein 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CABP2 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 1:201,374,649...201,380,469
Ensembl chr 1:201,375,276...201,380,469
|
|
G |
Cacna1h |
calcium voltage-gated channel subunit alpha1 H |
increases expression multiple interactions |
ISO |
Cyclophosphamide results in increased expression of CACNA1H protein 3-cyanoalanine inhibits the reaction [[N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine co-treated with Cyclophosphamide] results in increased expression of CACNA1H protein]; [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine co-treated with Cyclophosphamide] results in increased expression of CACNA1H protein |
CTD |
PMID:29129814 |
|
NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
increases expression multiple interactions |
EXP |
Cyclophosphamide results in increased expression of CALCA protein O-1602 compound inhibits the reaction [Cyclophosphamide results in increased expression of CALCA protein] |
CTD |
PMID:32615180 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Calr |
calreticulin |
increases expression decreases expression |
EXP |
Cyclophosphamide results in increased expression of CALR mRNA; Cyclophosphamide results in increased expression of CALR protein Cyclophosphamide results in decreased expression of CALR mRNA |
CTD |
PMID:11599041 PMID:11906922 PMID:15928459 PMID:18246545 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Canx |
calnexin |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CANX mRNA |
CTD |
PMID:11906922 |
|
NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821
|
|
G |
Capn2 |
calpain 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CAPN2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969
|
|
G |
Car12 |
carbonic anhydrase 12 |
multiple interactions |
ISO |
CA12 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 8:67,274,739...67,330,428
Ensembl chr 8:67,274,359...67,330,440
|
|
G |
Car2 |
carbonic anhydrase 2 |
decreases expression increases expression |
ISO |
Cyclophosphamide results in decreased expression of CA2 mRNA Cyclophosphamide results in increased expression of CAR2 mRNA |
CTD |
PMID:15331540 PMID:17403535 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Car3 |
carbonic anhydrase 3 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CA3 protein |
CTD |
PMID:15928459 |
|
NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
|
|
G |
Car7 |
carbonic anhydrase 7 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CAR7 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr19:429,063...438,478
Ensembl chr19:429,075...438,467
|
|
G |
Cars1 |
cysteinyl-tRNA synthetase 1 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of CARS1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 1:198,753,689...198,796,016
Ensembl chr 1:198,753,691...198,795,941
|
|
G |
Casp1 |
caspase 1 |
decreases expression increases expression multiple interactions |
ISO EXP |
Cyclophosphamide results in decreased expression of CASP1 mRNA Cyclophosphamide results in increased expression of CASP1 mRNA Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CASP1 protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CASP1 protein] |
CTD |
PMID:17403535 PMID:21041162 PMID:35762198 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions decreases response to substance increases expression increases activity increases cleavage |
ISO EXP |
[Bortezomib co-treated with oblimersen co-treated with Cyclophosphamide] results in increased activity of CASP3 protein; BCL2 protein inhibits the reaction [Cyclophosphamide results in increased activity of CASP3 protein]; Cyclophosphamide promotes the reaction [SGI-1027 results in increased cleavage of CASP3 protein]; Cyclophosphamide results in increased cleavage of and results in increased activity of CASP3 protein; PAX5 protein affects the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein]; SGI-1027 promotes the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein]; Valproic Acid inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein] CASP3 protein alternative form results in decreased susceptibility to Cyclophosphamide Cyclophosphamide results in increased expression of CASP3 mRNA Fenofibrate inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of CASP3 protein]; levocabastine inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein] Cilostazol inhibits the reaction [Cyclophosphamide results in increased expression of CASP3 protein]; Cyclophosphamide results in increased expression of and results in increased activity of CASP3 protein; herbacetin inhibits the reaction [Cyclophosphamide results in increased expression of CASP3 mRNA]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein]]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of and results in increased activity of CASP3 protein]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased activity of CASP3 protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased activity of CASP3 protein] Cyclophosphamide results in increased expression of CASP3 mRNA; Cyclophosphamide results in increased expression of CASP3 protein |
CTD |
PMID:11723234 PMID:14503796 PMID:16675587 PMID:17020986 PMID:17898787 PMID:30506662 PMID:32197949 PMID:32456565 PMID:34658283 PMID:35762198 PMID:36198566 PMID:37419146 PMID:38278497 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
increases cleavage multiple interactions |
EXP |
Cyclophosphamide results in increased cleavage of CASP4 protein sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP4 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP4 protein] |
CTD |
PMID:32197949 |
|
NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases response to substance |
ISO |
[Methotrexate results in increased expression of CASP8 protein] which results in increased susceptibility to Cyclophosphamide metabolite; Cyclophosphamide metabolite results in increased expression of and results in increased cleavage of CASP8 protein; Cyclophosphamide results in increased cleavage of and results in increased activity of CASP8 protein CASP8 protein results in increased susceptibility to Cyclophosphamide metabolite |
CTD |
PMID:17898787 PMID:22010212 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity increases expression |
ISO EXP |
BCL2 protein inhibits the reaction [Cyclophosphamide results in increased activity of CASP9 protein]; Cyclophosphamide results in increased cleavage of and results in increased activity of CASP9 protein Cyclophosphamide results in increased expression of CASP9 protein ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of CASP9 protein] |
CTD |
PMID:11723234 PMID:17898787 PMID:30506662 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
decreases expression multiple interactions affects activity decreases activity |
EXP ISO |
Cyclophosphamide results in decreased expression of CAT protein herbacetin inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; mangiferin inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; naringin inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; Pentoxifylline inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; pimagedine inhibits the reaction [Cyclophosphamide results in decreased expression of CAT protein]; Quercetin inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; Rutin inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; thymoquinone inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein] Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of CAT protein]; cinnamic acid inhibits the reaction [Cyclophosphamide affects the activity of CAT protein]; Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of CAT protein]; Eicosapentaenoic Acid inhibits the reaction [Cyclophosphamide affects the activity of CAT protein]; Fenofibrate inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; levocabastine inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; NFE2L2 gene mutant form promotes the reaction [Cyclophosphamide results in decreased expression of CAT protein]; Plant Extracts inhibits the reaction [Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of CAT protein]]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of CAT mRNA] Cyclophosphamide results in decreased expression of CAT mRNA; Cyclophosphamide results in decreased expression of CAT protein |
CTD |
PMID:16076520 PMID:19107871 PMID:20052769 PMID:20957680 PMID:21772021 PMID:22285266 PMID:23542512 PMID:23695977 PMID:25753322 PMID:27633142 PMID:29753871 PMID:33992719 PMID:34748891 PMID:35906875 PMID:36198566 PMID:38278497 More...
|
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccin |
calicin |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CCIN protein |
CTD |
PMID:17475930 |
|
NCBI chr 5:58,206,676...58,208,563
Ensembl chr 5:58,206,633...58,208,951
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression increases expression multiple interactions |
EXP ISO |
Cyclophosphamide results in decreased expression of CCL2 protein Cyclophosphamide results in increased expression of CCL2 mRNA naringin inhibits the reaction [Cyclophosphamide results in increased expression of CCL2 mRNA] Cyclophosphamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL2 protein] |
CTD |
PMID:18848347 PMID:21068404 PMID:33992719 PMID:36416909 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl25 |
C-C motif chemokine ligand 25 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CCL25 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr12:2,707,398...2,716,571
Ensembl chr12:2,707,398...2,716,554
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of CCL3 protein Cyclophosphamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL3 protein] |
CTD |
PMID:21880982 PMID:36416909 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CCL7 mRNA |
CTD |
PMID:15331540 PMID:21041162 |
|
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
|
|
G |
Ccn1 |
cellular communication network factor 1 |
decreases expression multiple interactions |
EXP |
Cyclophosphamide results in decreased expression of CCN1 mRNA; Cyclophosphamide results in decreased expression of CCN1 protein Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of CCN1 mRNA]; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of CCN1 protein] |
CTD |
PMID:36154502 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccn2 |
cellular communication network factor 2 |
decreases expression multiple interactions |
EXP |
Cyclophosphamide results in decreased expression of CCN2 mRNA; Cyclophosphamide results in decreased expression of CCN2 protein Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of CCN2 mRNA]; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of CCN2 protein] |
CTD |
PMID:36154502 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CCNA2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CCND1 protein |
CTD |
PMID:33737021 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CCND2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CCND3 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccr5 |
C-C motif chemokine receptor 5 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CCR5 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260
|
|
G |
Ccr8 |
C-C motif chemokine receptor 8 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CCR8 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 8:119,826,332...119,828,292
Ensembl chr 8:119,826,568...119,827,629
|
|
G |
Ccr9 |
C-C motif chemokine receptor 9 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CCR9 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 8:123,396,157...123,410,199
Ensembl chr 8:123,395,813...123,413,969
|
|
G |
Cct3 |
chaperonin containing TCP1 subunit 3 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CCT3 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 2:173,765,701...173,790,353
Ensembl chr 2:173,765,698...173,790,757
|
|
G |
Cct5 |
chaperonin containing TCP1 subunit 5 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CCT5 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 2:82,591,750...82,602,903
Ensembl chr 2:82,590,630...82,602,930
|
|
G |
Cct7 |
chaperonin containing TCP1 subunit 7 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CCT7 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 4:117,989,232...118,006,478
Ensembl chr 4:117,989,232...118,006,580
|
|
G |
Cd14 |
CD14 molecule |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CD14 mRNA |
CTD |
PMID:15331540 PMID:21041162 |
|
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
|
|
G |
Cd151 |
CD151 molecule (Raph blood group) |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CD151 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:196,564,744...196,568,753
Ensembl chr 1:196,565,181...196,568,753
|
|
G |
Cd2 |
Cd2 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 2:188,710,895...188,724,044
Ensembl chr 2:188,710,900...188,724,026
|
|
G |
Cd27 |
CD27 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD27 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 4:158,030,700...158,035,862
Ensembl chr 4:158,030,703...158,035,592
|
|
G |
Cd28 |
Cd28 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD28 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 9:62,166,324...62,194,674
Ensembl chr 9:62,166,192...62,194,685
|
|
G |
Cd38 |
CD38 molecule |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CD38 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986
|
|
G |
Cd3d |
CD3 delta subunit of T-cell receptor complex |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD3D mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 8:45,287,803...45,293,342
Ensembl chr 8:45,288,749...45,301,809
|
|
G |
Cd3e |
CD3 epsilon subunit of T-cell receptor complex |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD3E mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 8:45,303,848...45,315,005
Ensembl chr 8:45,303,852...45,315,022
|
|
G |
Cd3g |
CD3 gamma subunit of T-cell receptor complex |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD3G mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 8:45,280,797...45,287,271
Ensembl chr 8:45,281,204...45,287,147
|
|
G |
Cd4 |
Cd4 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD4 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 4:157,668,878...157,695,366
|
|
G |
Cd40 |
CD40 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD40 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd5 |
Cd5 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD5 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:207,365,337...207,386,313
Ensembl chr 1:207,365,337...207,386,313
|
|
G |
Cd6 |
Cd6 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD6 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:207,442,873...207,481,703
Ensembl chr 1:207,442,877...207,481,634
|
|
G |
Cd69 |
Cd69 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD69 mRNA Cyclophosphamide metabolite results in decreased expression of CD69 mRNA |
CTD |
PMID:21041162 PMID:24356939 |
|
NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542
|
|
G |
Cd74 |
CD74 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD74 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003
|
|
G |
Cd79b |
CD79b molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD79B mRNA |
CTD |
PMID:15331540 |
|
NCBI chr10:91,239,354...91,242,500
Ensembl chr10:91,239,356...91,242,625
|
|
G |
Cd83 |
CD83 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD83 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083
|
|
G |
Cd84 |
CD84 molecule |
increases expression |
ISO |
Cyclophosphamide metabolite results in increased expression of CD84 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr13:84,327,580...84,367,153
Ensembl chr13:84,327,553...84,362,076
|
|
G |
Cd8a |
CD8 subunit alpha |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD8A mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 4:103,365,804...103,370,041
Ensembl chr 4:103,365,804...103,370,040
|
|
G |
Cd8b |
CD8 subunit beta |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD8B1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 4:103,312,596...103,328,523
Ensembl chr 4:103,312,578...103,328,553
|
|
G |
Cdc20 |
cell division cycle 20 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CDC20 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
|
|
G |
Cdh1 |
cadherin 1 |
affects expression |
EXP |
Cyclophosphamide affects the expression of CDH1 mRNA |
CTD |
PMID:10859244 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
affects expression |
EXP |
Cyclophosphamide affects the expression of CDH2 mRNA |
CTD |
PMID:10859244 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdh3 |
cadherin 3 |
affects expression |
EXP |
Cyclophosphamide affects the expression of CDH3 mRNA |
CTD |
PMID:10859244 |
|
NCBI chr19:34,393,596...34,444,084
Ensembl chr19:34,393,727...34,444,084
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CDK2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CDKN1A mRNA |
CTD |
PMID:15331540 PMID:21527772 PMID:29445054 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of CDKN1B mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CDKN1C mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
|
|
G |
Cdkn2d |
cyclin dependent kinase inhibitor 2D |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CDKN2D mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 8:19,831,874...19,834,640
Ensembl chr 8:19,831,866...19,834,674
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of CEBPB mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cel |
carboxyl ester lipase |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CEL mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035
|
|
G |
Cfb |
complement factor B |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CFB mRNA |
CTD |
PMID:21041162 |
|
NCBI chr20:3,970,643...3,976,510
Ensembl chr20:3,951,474...3,976,505
|
|
G |
Cfi |
complement factor I |
affects response to substance |
ISO |
CFI protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 2:218,389,079...218,430,565
Ensembl chr 2:218,387,990...218,430,561
|
|
G |
Chac1 |
ChaC glutathione-specific gamma-glutamylcyclotransferase 1 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of CHAC1 mRNA; Cyclophosphamide results in decreased expression of CHAC1 mRNA |
CTD |
PMID:23824090 PMID:24356939 |
|
NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526
|
|
G |
Champ1 |
chromosome alignment maintaining phosphoprotein 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CHAMP1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr16:75,733,958...75,744,931
Ensembl chr16:75,733,805...75,744,984
|
|
G |
Chd5 |
chromodomain helicase DNA binding protein 5 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CHD5 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 5:162,848,273...162,898,997
Ensembl chr 5:162,848,394...162,896,291
|
|
G |
Chga |
chromogranin A |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CHGA mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 6:121,696,051...121,707,399
Ensembl chr 6:121,696,051...121,707,398
|
|
G |
Chrm5 |
cholinergic receptor, muscarinic 5 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CHRM5 protein |
CTD |
PMID:16125470 |
|
NCBI chr 3:99,284,846...99,337,252
Ensembl chr 3:99,284,846...99,337,252
|
|
G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
affects expression decreases expression |
EXP |
Cyclophosphamide affects the expression of CITED2 mRNA Cyclophosphamide results in decreased expression of CITED2 mRNA |
CTD |
PMID:18246545 |
|
NCBI chr 1:12,312,426...12,314,869
Ensembl chr 1:12,312,160...12,314,897
|
|
G |
Ckm |
creatine kinase, M-type |
multiple interactions increases expression |
EXP |
Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CKM protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CKM protein] |
CTD |
PMID:35762198 |
|
NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720
|
|
G |
Cldn1 |
claudin 1 |
multiple interactions decreases expression |
ISO |
Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of CLDN1 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of CLDN1 protein] |
CTD |
PMID:32151603 |
|
NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724
|
|
G |
Cldn4 |
claudin 4 |
multiple interactions decreases expression |
EXP |
Anthocyanins inhibits the reaction [Cyclophosphamide results in decreased expression of CLDN4 protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of CLDN4 protein] |
CTD |
PMID:25451569 |
|
NCBI chr12:21,751,638...21,753,436
Ensembl chr12:21,751,331...21,753,436
|
|
G |
Clic4 |
chloride intracellular channel 4 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CLIC4 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 5:147,453,702...147,513,455
Ensembl chr 5:147,453,712...147,513,452
|
|
G |
Clip1 |
CAP-GLY domain containing linker protein 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CLIP1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr12:32,910,932...33,017,891
Ensembl chr12:32,910,977...33,017,884
|
|
G |
Coch |
cochlin |
affects response to substance |
ISO |
COCH protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 6:69,031,139...69,045,124
Ensembl chr 6:69,031,167...69,045,109
|
|
G |
Comt |
catechol-O-methyltransferase |
increases expression |
ISO |
Cyclophosphamide results in increased expression of COMT mRNA |
CTD |
PMID:21041162 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Cox7a2 |
cytochrome c oxidase subunit 7A2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of COX7A2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 8:80,716,824...80,720,922
Ensembl chr14:51,301,168...51,301,633 Ensembl chr 8:51,301,168...51,301,633
|
|
G |
Crabp2 |
cellular retinoic acid binding protein 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CRABP2 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 2:173,417,004...173,421,352
Ensembl chr 2:173,416,857...173,421,379
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CREB1 protein modified form |
CTD |
PMID:18299998 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crem |
cAMP responsive element modulator |
decreases expression multiple interactions |
EXP |
Cyclophosphamide results in decreased expression of CREM mRNA; Cyclophosphamide results in decreased expression of CREM protein Drugs, Chinese Herbal inhibits the reaction [Cyclophosphamide results in decreased expression of CREM mRNA]; Drugs, Chinese Herbal inhibits the reaction [Cyclophosphamide results in decreased expression of CREM protein] |
CTD |
PMID:17624719 |
|
NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989
|
|
G |
Crh |
corticotropin releasing hormone |
increases expression |
EXP ISO |
Cyclophosphamide results in increased expression of CRH mRNA; Cyclophosphamide results in increased expression of CRH protein |
CTD |
PMID:15276878 PMID:16614059 PMID:17335920 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Crhr2 |
corticotropin releasing hormone receptor 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CRHR2 protein |
CTD |
PMID:16614059 |
|
NCBI chr 4:84,222,897...84,265,924
Ensembl chr 4:84,224,002...84,265,904
|
|
G |
Crp |
C-reactive protein |
multiple interactions increases secretion |
EXP |
allyl sulfide inhibits the reaction [Cyclophosphamide results in increased secretion of CRP protein] |
CTD |
PMID:31779506 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions |
ISO |
[Cyclophosphamide co-treated with Sizofiran] results in increased expression of CSF1 mRNA |
CTD |
PMID:10052129 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Csf2 |
colony stimulating factor 2 |
affects activity increases expression multiple interactions decreases expression |
ISO EXP |
CSF2 protein affects the activity of Cyclophosphamide Cyclophosphamide results in increased expression of CSF2 protein asperuloside inhibits the reaction [Cyclophosphamide results in decreased expression of CSF2 protein]; CSF2 protein inhibits the reaction [Cyclophosphamide results in decreased expression of EPO protein]; CSF2 protein inhibits the reaction [Cyclophosphamide results in decreased expression of KIT protein]; CSF2 protein inhibits the reaction [Cyclophosphamide results in decreased expression of THPO protein]; CSF2 protein inhibits the reaction [Cyclophosphamide results in increased phosphorylation of MTOR protein]; CSF2 protein promotes the reaction [Cyclophosphamide results in increased expression of BECN1 protein]; CSF2 protein promotes the reaction [Cyclophosphamide results in increased lipidation of MAP1LC3B protein]; CSF2 protein promotes the reaction [Cyclophosphamide results in increased phosphorylation of PRKAA1 protein]; dorsomorphin inhibits the reaction [asperuloside inhibits the reaction [Cyclophosphamide results in decreased expression of CSF2 protein]] |
CTD |
PMID:8349185 PMID:18848347 PMID:38348709 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csk |
C-terminal Src kinase |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CSK mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 8:58,029,748...58,048,742
Ensembl chr 8:58,029,749...58,048,292
|
|
G |
Cst7 |
cystatin F |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CST7 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 3:139,396,830...139,405,557
Ensembl chr 3:139,396,850...139,405,557
|
|
G |
Csta |
cystatin A |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of CSTA mRNA |
CTD |
PMID:24356939 |
|
NCBI chr11:64,620,483...64,631,488
Ensembl chr11:64,620,483...64,631,488
|
|
G |
Cth |
cystathionine gamma-lyase |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CTH protein |
CTD |
PMID:29129814 |
|
NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234
|
|
G |
Ctnnbip1 |
catenin, beta-interacting protein 1 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of CTNNBIP1 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 5:159,961,961...160,010,942
Ensembl chr 5:159,961,928...160,010,939
|
|
G |
Ctnnd2 |
catenin delta 2 |
multiple interactions |
ISO |
CTNND2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 2:81,168,525...82,016,495
Ensembl chr 2:81,167,117...82,015,764
|
|
G |
Ctsd |
cathepsin D |
multiple interactions increases activity |
ISO EXP |
[Cyclophosphamide co-treated with Mecamylamine] results in increased expression of CTSD mRNA Anthocyanins inhibits the reaction [Cyclophosphamide results in increased activity of CTSD protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased activity of CTSD protein] |
CTD |
PMID:18433785 PMID:25451569 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsh |
cathepsin H |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CTSH mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 8:90,608,941...90,627,824
Ensembl chr 8:90,608,941...90,627,824
|
|
G |
Ctsl |
cathepsin L |
increases expression multiple interactions decreases expression |
ISO |
Cyclophosphamide results in increased expression of CTSL mRNA 5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline inhibits the reaction [Cyclophosphamide results in decreased expression of CTSL mRNA] |
CTD |
PMID:17403535 PMID:30760223 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Cx3cl1 |
C-X3-C motif chemokine ligand 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CX3CL1 protein |
CTD |
PMID:16651033 |
|
NCBI chr19:10,227,337...10,237,826
Ensembl chr19:10,227,340...10,236,833
|
|
G |
Cx3cr1 |
C-X3-C motif chemokine receptor 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CX3CR1 protein |
CTD |
PMID:16651033 |
|
NCBI chr 8:119,785,726...119,799,431
Ensembl chr 8:119,782,595...119,800,014
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CXCL1 protein |
CTD |
PMID:18848347 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
affects expression increases response to substance increases expression |
ISO |
Cyclophosphamide affects the expression of CXCL10 mRNA CXCL10 protein results in increased susceptibility to Cyclophosphamide Cyclophosphamide results in increased expression of CXCL10 protein |
CTD |
PMID:18957084 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CXCL11 protein |
CTD |
PMID:18957084 |
|
NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
affects expression increases expression |
ISO EXP |
Cyclophosphamide affects the expression of CXCL12 mRNA Cyclophosphamide results in increased expression of CXCL12 mRNA Cyclophosphamide results in increased expression of CXCL12 mRNA; Cyclophosphamide results in increased expression of CXCL12 protein |
CTD |
PMID:12624490 PMID:16337237 PMID:19066630 PMID:20032115 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[Cyclophosphamide co-treated with Dexamethasone] inhibits the reaction [Paraquat results in increased expression of CXCL2 mRNA] |
CTD |
PMID:36031164 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
increases expression multiple interactions affects expression |
ISO |
Cyclophosphamide results in increased expression of CXCL1 mRNA; Cyclophosphamide results in increased expression of CXCL1 protein VIP protein inhibits the reaction [Cyclophosphamide results in increased expression of CXCL1 protein] Cyclophosphamide affects the expression of CXCL3 mRNA |
CTD |
PMID:15331540 PMID:18483878 PMID:18957084 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcl6 |
C-X-C motif chemokine ligand 6 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CXCL5 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr14:17,310,790...17,312,250
Ensembl chr14:17,310,426...17,313,093
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
affects expression increases expression decreases expression |
ISO |
Cyclophosphamide affects the expression of CXCL9 mRNA Cyclophosphamide results in increased expression of CXCL9 mRNA; Cyclophosphamide results in increased expression of CXCL9 protein Cyclophosphamide results in decreased expression of CXCL9 protein |
CTD |
PMID:15331540 PMID:18957084 PMID:21041162 PMID:21880982 |
|
NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
multiple interactions affects localization increases expression decreases expression |
EXP ISO |
Cyclophosphamide promotes the reaction [MIF protein binds to CXCR4 protein] Cyclophosphamide affects the localization of CXCR4 protein Cyclophosphamide results in increased expression of CXCR4 mRNA; Cyclophosphamide results in increased expression of CXCR4 protein Cyclophosphamide results in decreased expression of CXCR4 mRNA |
CTD |
PMID:19066630 PMID:20032115 PMID:21041162 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cxcr6 |
C-X-C motif chemokine receptor 6 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CXCR6 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 8:123,434,417...123,439,568
Ensembl chr 8:123,416,325...123,439,526
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
decreases expression multiple interactions |
EXP |
Cyclophosphamide results in decreased expression of CYP11A1 mRNA [Rutin co-treated with Chitosan] inhibits the reaction [Cyclophosphamide results in decreased expression of CYP11A1 mRNA] |
CTD |
PMID:38211767 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Cyclophosphamide results in decreased activity of CYP1A1 protein |
CTD |
PMID:18420780 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
ISO |
Cyclophosphamide results in decreased activity of CYP1A2 protein |
CTD |
PMID:18420780 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CYP1B1 mRNA |
CTD |
PMID:12167460 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2a3 |
cytochrome P450, family 2, subfamily a, polypeptide 3 |
decreases activity |
ISO |
Cyclophosphamide results in decreased activity of CYP2A4 protein |
CTD |
PMID:18420780 |
|
NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions increases metabolic processing increases expression increases hydroxylation increases activity affects metabolic processing increases response to substance |
EXP |
Cyclophosphamide results in increased expression of and results in increased activity of CYP2B1 protein; Metyrapone inhibits the reaction [CYP2B1 results in increased susceptibility to Cyclophosphamide] CYP2B1 protein results in increased metabolism of Cyclophosphamide; CYP2B1 results in increased metabolism of Cyclophosphamide Cyclophosphamide results in increased expression of CYP2B1 mRNA; Cyclophosphamide results in increased expression of CYP2B1 protein CYP2B1 protein mutant form results in increased hydroxylation of Cyclophosphamide; CYP2B1 protein results in increased hydroxylation of Cyclophosphamide CYP2B1 results in increased activity of Cyclophosphamide CYP2B1 protein affects the metabolism of Cyclophosphamide CYP2B1 protein results in increased susceptibility to Cyclophosphamide; CYP2B1 results in increased susceptibility to Cyclophosphamide |
CTD |
PMID:2272335 PMID:7834628 PMID:8640822 PMID:9592392 PMID:10415877 PMID:11221871 PMID:11933215 PMID:15102956 PMID:15635577 PMID:16019949 PMID:17634551 PMID:19103281 PMID:20566340 More...
|
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CYP2B2 mRNA; Cyclophosphamide results in increased expression of CYP2B2 protein |
CTD |
PMID:16019949 PMID:17634551 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions affects hydroxylation increases hydroxylation increases response to substance increases activity increases metabolic processing increases expression |
ISO EXP |
[Cyclophosphamide results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA; [Doxorubicin co-treated with Cyclophosphamide] affects the expression of CYP2B6 mRNA; Cyclophosphamide results in decreased expression of and results in decreased activity of CYP2B6 protein; CYP2B6 protein polymorphism affects the activity of and affects the susceptibility to Cyclophosphamide; CYP2B6 protein results in increased metabolism of and results in increased susceptibility to Cyclophosphamide; POR promotes the reaction [CYP2B6 results in increased susceptibility to Cyclophosphamide]; POR protein promotes the reaction [CYP2B6 protein results in increased susceptibility to Cyclophosphamide] CYP2B6 intron polymorphism affects the hydroxylation of Cyclophosphamide; CYP2B6 promoter polymorphism affects the hydroxylation of Cyclophosphamide CYP2B6 protein results in increased hydroxylation of Cyclophosphamide CYP2B6 protein results in increased susceptibility to Cyclophosphamide; CYP2B6 results in increased susceptibility to Cyclophosphamide CYP2B6 protein results in increased activity of Cyclophosphamide CYP2B6 protein results in increased metabolism of Cyclophosphamide Cyclophosphamide results in increased expression of CYP2B10 mRNA |
CTD |
PMID:9766669 PMID:10919648 PMID:11389073 PMID:11723234 PMID:12498089 PMID:12872138 PMID:15248218 PMID:15769884 PMID:16183265 PMID:16322899 PMID:17041008 PMID:17502835 PMID:18212249 PMID:18633247 PMID:24819615 PMID:25860621 More...
|
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
increases expression increases metabolic processing multiple interactions increases response to substance increases activity |
EXP ISO |
Cyclophosphamide results in increased expression of CYP2C11 mRNA CYP2C11 results in increased metabolism of Cyclophosphamide POR promotes the reaction [CYP2C18 results in increased susceptibility to Cyclophosphamide] CYP2C18 results in increased activity of Cyclophosphamide |
CTD |
PMID:9241661 PMID:9766669 PMID:16019949 PMID:20566340 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
increases metabolic processing decreases metabolic processing multiple interactions increases activity increases hydroxylation increases response to substance increases expression |
EXP ISO |
CYP2C6 results in increased metabolism of Cyclophosphamide CYP2C19 gene polymorphism results in decreased metabolism of Cyclophosphamide [CYP2C19 protein results in increased hydroxylation of Cyclophosphamide] which results in increased chemical synthesis of 4-hydroxycyclophosphamide; [CYP2C19 protein results in increased hydroxylation of Cyclophosphamide] which results in increased chemical synthesis of Acrolein; CYP2C19 protein polymorphism affects the activity of and affects the susceptibility to Cyclophosphamide CYP2C19 protein results in increased metabolism of Cyclophosphamide CYP2C19 results in increased activity of Cyclophosphamide CYP2C19 protein results in increased susceptibility to Cyclophosphamide Cyclophosphamide results in increased expression of CYP2C29 mRNA |
CTD |
PMID:9241661 PMID:15248218 PMID:16116487 PMID:20566340 PMID:24819615 PMID:30500380 More...
|
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
increases activity |
ISO |
CYP2C8 results in increased activity of Cyclophosphamide |
CTD |
PMID:9241661 |
|
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
increases metabolic processing |
ISO |
CYP2D6 protein results in increased metabolism of Cyclophosphamide |
CTD |
PMID:11377097 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
increases metabolic processing |
EXP |
CYP2E1 results in increased metabolism of Cyclophosphamide |
CTD |
PMID:20566340 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression multiple interactions increases metabolic processing affects response to substance affects metabolic processing increases hydroxylation increases response to substance |
EXP ISO |
Cyclophosphamide results in increased expression of CYP3A2 mRNA; Cyclophosphamide results in increased expression of CYP3A2 protein [Cyclophosphamide results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [CYP3A4 protein results in increased hydroxylation of Cyclophosphamide] which results in increased chemical synthesis of 4-hydroxycyclophosphamide; [CYP3A4 protein results in increased hydroxylation of Cyclophosphamide] which results in increased chemical synthesis of Acrolein; CYP3A4 gene affects the susceptibility to [Carmustine co-treated with Cyclophosphamide co-treated with Cisplatin]; CYP3A4 protein results in increased metabolism of and results in increased susceptibility to Cyclophosphamide CYP3A4 protein results in increased metabolism of Cyclophosphamide CYP3A4 gene polymorphism affects the susceptibility to Cyclophosphamide CYP3A4 protein affects the metabolism of Cyclophosphamide CYP3A4 protein results in increased susceptibility to Cyclophosphamide Cyclophosphamide results in increased expression of CYP3A4 mRNA |
CTD |
PMID:11377097 PMID:16019949 PMID:16087946 PMID:17041008 PMID:18839173 PMID:25860621 PMID:26718876 PMID:30500380 More...
|
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
affects expression decreases expression |
EXP |
Cyclophosphamide affects the expression of CYP3A23-3A1 mRNA Cyclophosphamide results in decreased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:18246545 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
affects metabolic processing affects response to substance multiple interactions increases expression |
ISO |
CYP3A5 protein affects the metabolism of Cyclophosphamide CYP3A5 gene polymorphism affects the susceptibility to Cyclophosphamide CYP3A5 gene affects the susceptibility to [Carmustine co-treated with Cyclophosphamide co-treated with Cisplatin] Cyclophosphamide results in increased expression of CYP3A13 mRNA |
CTD |
PMID:16087946 PMID:24819615 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Dcn |
decorin |
multiple interactions |
ISO |
DCN protein inhibits the reaction [TGFB1 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Cisplatin co-treated with Melphalan co-treated with Thiotepa]] |
CTD |
PMID:9509296 |
|
NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
|
|
G |
Ddb1 |
damage-specific DNA binding protein 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of DDB1 mRNA |
CTD |
PMID:11056294 |
|
NCBI chr 1:207,252,890...207,278,685
Ensembl chr 1:207,252,890...207,278,676
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
affects expression decreases expression multiple interactions increases expression |
EXP ISO |
Cyclophosphamide affects the expression of DDIT3 mRNA Cyclophosphamide metabolite results in decreased expression of DDIT3 mRNA sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased expression of DDIT3 mRNA]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased expression of DDIT3 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of DDIT3 mRNA]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of DDIT3 protein] Cyclophosphamide results in increased expression of DDIT3 mRNA; Cyclophosphamide results in increased expression of DDIT3 protein |
CTD |
PMID:18246545 PMID:24356939 PMID:32197949 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
affects response to substance |
ISO |
DDIT4 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Deaf1 |
DEAF1 transcription factor |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of DEAF1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 1:196,401,857...196,435,541
Ensembl chr 1:196,401,857...196,435,541
|
|
G |
Dlc1 |
DLC1 Rho GTPase activating protein |
increases expression |
ISO |
Cyclophosphamide results in increased expression of DLC1 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr16:55,246,716...55,671,441
Ensembl chr16:55,291,584...55,671,439
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
affects expression increases expression |
EXP ISO |
Cyclophosphamide affects the expression of DNAJB1 mRNA Cyclophosphamide metabolite results in increased expression of DNAJB1 mRNA |
CTD |
PMID:18246545 PMID:24356939 |
|
NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458
|
|
G |
Dnajb4 |
DnaJ heat shock protein family (Hsp40) member B4 |
increases expression |
ISO |
Cyclophosphamide metabolite results in increased expression of DNAJB4 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 2:241,129,346...241,159,272
Ensembl chr 2:241,130,340...241,159,089
|
|
G |
Dnajb6 |
DnaJ heat shock protein family (Hsp40) member B6 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of DNAJB6 protein |
CTD |
PMID:17475930 |
|
NCBI chr 4:5,452,683...5,556,679
Ensembl chr 4:5,452,683...5,556,659
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions decreases methylation increases expression decreases expression |
ISO |
Cyclophosphamide promotes the reaction [KDM1A protein results in decreased methylation of and results in decreased degradation of DNMT1 protein]; SGI-1027 promotes the reaction [Cyclophosphamide results in decreased expression of DNMT1 protein] Cyclophosphamide results in decreased methylation of DNMT1 protein Cyclophosphamide results in increased expression of DNMT1 protein |
CTD |
PMID:22007908 PMID:34658283 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dnmt3b |
DNA methyltransferase 3 beta |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of DNMT3B protein SGI-1027 promotes the reaction [Cyclophosphamide results in decreased expression of DNMT3B protein] |
CTD |
PMID:34658283 |
|
NCBI chr 3:142,130,588...142,169,128
Ensembl chr 3:142,130,592...142,169,124
|
|
G |
Dntt |
DNA nucleotidylexotransferase |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of DNTT mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:239,856,391...239,888,283
Ensembl chr 1:239,856,391...239,888,282
|
|
G |
Dpf3 |
double PHD fingers 3 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of DPF3 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 6:102,841,403...103,125,558
Ensembl chr 6:102,846,029...103,125,493
|
|
G |
Dpysl4 |
dihydropyrimidinase-like 4 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of DPYSL4 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:193,883,039...193,898,916
Ensembl chr 1:193,883,106...193,898,914
|
|
G |
Drd1 |
dopamine receptor D1 |
affects binding |
ISO |
Cyclophosphamide binds to DRD1 protein |
CTD |
PMID:11180191 |
|
NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
|
|
G |
Drd2 |
dopamine receptor D2 |
affects binding |
ISO |
Cyclophosphamide binds to DRD2 protein |
CTD |
PMID:11180191 |
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Dusp10 |
dual specificity phosphatase 10 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of DUSP10 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr13:95,613,716...95,651,716
Ensembl chr13:95,614,292...95,651,716
|
|
G |
Dusp2 |
dual specificity phosphatase 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of DUSP2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 3:114,556,325...114,558,510
Ensembl chr 3:114,556,325...114,558,499
|
|
G |
Dzip1 |
DAZ interacting zinc finger protein 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of DZIP1 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr15:95,956,329...96,009,994
Ensembl chr15:95,956,398...96,010,066
|
|
G |
E2f3 |
E2F transcription factor 3 |
multiple interactions |
ISO |
E2F3 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr17:34,601,756...34,679,139
Ensembl chr17:34,601,830...34,676,253
|
|
G |
Eda2r |
ectodysplasin A2 receptor |
increases expression |
ISO |
Cyclophosphamide results in increased expression of EDA2R mRNA |
CTD |
PMID:21527772 |
|
NCBI chr X:62,224,763...62,269,333
Ensembl chr X:62,228,229...62,269,268
|
|
G |
Edn1 |
endothelin 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of EDN1 protein |
CTD |
PMID:17562616 PMID:18548196 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Ednrb |
endothelin receptor type B |
increases expression |
ISO |
Cyclophosphamide results in increased expression of EDNRB mRNA |
CTD |
PMID:20849824 |
|
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of EEF2 mRNA |
CTD |
PMID:18246545 |
|
NCBI chr 7:8,533,248...8,538,518
Ensembl chr 7:8,533,116...8,559,183
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
EGFR protein affects the susceptibility to [Cyclophosphamide co-treated with Doxorubicin co-treated with Fluorouracil] |
CTD |
PMID:15981280 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
increases expression decreases expression multiple interactions |
ISO EXP |
Cyclophosphamide results in increased expression of EGR1 mRNA Cyclophosphamide results in decreased expression of EGR1 mRNA Cyclophosphamide results in increased expression of EGR1 protein 3-cyanoalanine inhibits the reaction [[N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine co-treated with Cyclophosphamide] results in increased expression of EGR1 protein]; [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine co-treated with Cyclophosphamide] results in increased expression of EGR1 protein |
CTD |
PMID:7498375 PMID:9776515 PMID:21041162 PMID:21527772 PMID:29129814 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Egr2 |
early growth response 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of EGR2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Egr4 |
early growth response 4 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of EGR4 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 4:118,047,869...118,050,328
Ensembl chr 4:118,047,869...118,050,328
|
|
G |
Eif1ax |
eukaryotic translation initiation factor 1A, X-linked |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of EIF1AX mRNA |
CTD |
PMID:16322899 |
|
NCBI chr X:35,498,698...35,513,402
Ensembl chr X:35,498,517...35,513,335
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases phosphorylation multiple interactions |
EXP |
Cyclophosphamide results in increased phosphorylation of EIF2AK3 protein sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased phosphorylation of EIF2AK3 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:32197949 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of EIF4EBP1 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Elovl2 |
ELOVL fatty acid elongase 2 |
affects response to substance |
ISO |
ELOVL2 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr17:23,544,598...23,584,855
Ensembl chr17:23,544,568...23,584,848
|
|
G |
Emp1 |
epithelial membrane protein 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of EMP1 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 4:168,212,901...168,233,039
Ensembl chr 4:168,212,861...168,232,904
|
|
G |
Emp3 |
epithelial membrane protein 3 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of EMP3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:96,388,651...96,391,946
Ensembl chr 1:96,388,652...96,391,988
|
|
G |
Epb41l2 |
erythrocyte membrane protein band 4.1-like 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of EPB41L2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 1:19,863,010...20,037,795
Ensembl chr 1:19,863,009...20,037,721
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
affects expression increases expression |
EXP |
Cyclophosphamide affects the expression of EPHX1 mRNA Cyclophosphamide results in increased expression of EPHX1 mRNA |
CTD |
PMID:18246545 |
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Epo |
erythropoietin |
multiple interactions decreases expression increases response to substance |
EXP ISO |
angelicae sinensis extract inhibits the reaction [Cyclophosphamide results in decreased expression of EPO mRNA]; Astragali compound inhibits the reaction [Cyclophosphamide results in decreased expression of EPO mRNA] EPO protein results in increased susceptibility to Cyclophosphamide Cyclophosphamide results in decreased expression of EPO protein asperuloside inhibits the reaction [Cyclophosphamide results in decreased expression of EPO protein]; CSF2 protein inhibits the reaction [Cyclophosphamide results in decreased expression of EPO protein]; dorsomorphin inhibits the reaction [asperuloside inhibits the reaction [Cyclophosphamide results in decreased expression of EPO protein]] |
CTD |
PMID:11245434 PMID:19627214 PMID:38348709 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Erap1 |
endoplasmic reticulum aminopeptidase 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of ERAP1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 2:3,931,817...3,970,735
Ensembl chr 2:3,931,904...3,972,447
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
ISO |
ERBB2 affects the susceptibility to [Doxorubicin co-treated with Cyclophosphamide co-treated with docetaxel]; ERBB2 protein affects the susceptibility to [Cyclophosphamide co-treated with Doxorubicin co-treated with docetaxel]; ERBB2 protein affects the susceptibility to [Cyclophosphamide co-treated with pirarubicin co-treated with Fluorouracil]; ERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]; ERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide]; ERBB2 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Thiotepa co-treated with Carboplatin] |
CTD |
PMID:9816327 PMID:15834928 PMID:15940066 PMID:16446318 PMID:16682728 PMID:17010609 More...
|
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
multiple interactions |
ISO |
ERBB4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595
|
|
G |
Ercc1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
affects expression |
EXP |
Cyclophosphamide affects the expression of ERCC1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963
|
|
G |
Ercc2 |
ERCC excision repair 2, TFIIH core complex helicase subunit |
affects expression multiple interactions increases expression |
EXP ISO |
Cyclophosphamide affects the expression of ERCC2 mRNA 5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline inhibits the reaction [Cyclophosphamide results in increased expression of ERCC2 mRNA] |
CTD |
PMID:11906922 PMID:30760223 |
|
NCBI chr 1:79,033,342...79,047,102
Ensembl chr 1:79,033,326...79,047,102
|
|
G |
Erg |
ETS transcription factor ERG |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ERG mRNA |
CTD |
PMID:17403535 |
|
NCBI chr11:34,678,614...34,900,951
Ensembl chr11:34,678,618...34,845,871
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
increases phosphorylation multiple interactions |
EXP |
Cyclophosphamide results in increased phosphorylation of ERN1 protein sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased phosphorylation of ERN1 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased phosphorylation of ERN1 protein] |
CTD |
PMID:32197949 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] results in increased expression of ESR1 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] results in increased expression of ESR2 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Esrra |
estrogen related receptor, alpha |
decreases expression increases expression |
EXP |
Cyclophosphamide results in decreased expression of ESRRA mRNA Cyclophosphamide results in increased expression of ESRRA mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
Evi2a |
ecotropic viral integration site 2A |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of EVI2A mRNA |
CTD |
PMID:24356939 |
|
NCBI chr10:64,485,760...64,489,660
Ensembl chr10:64,485,200...64,489,843
|
|
G |
F2rl1 |
F2R like trypsin receptor 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of F2RL1 protein |
CTD |
PMID:15643279 |
|
NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226
|
|
G |
F2rl2 |
coagulation factor II (thrombin) receptor-like 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of F2RL2 protein |
CTD |
PMID:15643279 |
|
NCBI chr 2:26,972,054...26,977,098
Ensembl chr 2:26,972,054...26,977,098
|
|
G |
F2rl3 |
F2R like thrombin or trypsin receptor 3 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of F2RL3 protein |
CTD |
PMID:15643279 |
|
NCBI chr16:17,117,441...17,119,434
Ensembl chr16:17,117,441...17,119,472
|
|
G |
F3 |
coagulation factor III, tissue factor |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of F3 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fam107b |
family with sequence similarity 107, member B |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of FAM107B mRNA |
CTD |
PMID:24356939 |
|
NCBI chr17:74,478,608...74,685,027
Ensembl chr17:74,478,608...74,684,989
|
|
G |
Fam234b |
family with sequence similarity 234, member B |
multiple interactions |
ISO |
FAM234B mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 4:168,048,313...168,124,017
Ensembl chr 4:168,048,396...168,097,338
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions increases expression decreases expression |
ISO EXP |
[Cyclophosphamide co-treated with cacalol] results in decreased expression of FAS protein; [Cyclophosphamide co-treated with NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt] results in increased expression of FAS Cyclophosphamide results in increased expression of FAS Cyclophosphamide results in increased expression of FAS mRNA; Cyclophosphamide results in increased expression of FAS protein Cyclophosphamide metabolite results in decreased expression of FAS mRNA Plant Extracts inhibits the reaction [Cyclophosphamide results in increased expression of FAS mRNA] |
CTD |
PMID:10393266 PMID:16166447 PMID:20665104 PMID:24356939 PMID:25446862 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
[Cyclophosphamide co-treated with NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt] results in increased expression of FASLG |
CTD |
PMID:16166447 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fau |
FAU ubiquitin like and ribosomal protein S30 fusion |
increases expression |
EXP |
Cyclophosphamide results in increased expression of FAU mRNA |
CTD |
PMID:11599041 |
|
NCBI chr 1:203,350,226...203,351,741
Ensembl chr 1:203,350,189...203,351,742
|
|
G |
Fbxo40 |
F-box protein 40 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of FBXO40 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr11:63,794,452...63,812,697
Ensembl chr11:63,794,624...63,812,697
|
|
G |
Fbxw7 |
F-box and WD repeat domain containing 7 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FBXW7 mRNA |
CTD |
PMID:29445054 |
|
NCBI chr 2:170,149,706...170,311,536
Ensembl chr 2:170,149,694...170,309,941
|
|
G |
Fcer1g |
Fc epsilon receptor Ig |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FCER1G mRNA |
CTD |
PMID:21041162 |
|
NCBI chr13:83,649,447...83,654,248
Ensembl chr13:83,649,449...83,671,443
|
|
G |
Fcgr2a |
Fc gamma receptor 2A |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FCGR3 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr13:83,280,782...83,297,535
Ensembl chr13:83,280,784...83,295,967
|
|
G |
Fcgrt |
Fc gamma receptor and transporter |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FCGRT mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:95,574,436...95,584,171
Ensembl chr 1:95,567,175...95,584,084
|
|
G |
Fhl1 |
four and a half LIM domains 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of FHL1 mRNA |
CTD |
PMID:23558518 |
|
NCBI chr X:134,555,399...134,614,930
Ensembl chr X:134,555,479...134,614,928
|
|
G |
Fkbp1b |
FKBP prolyl isomerase 1B |
affects response to substance |
ISO |
FKBP1B protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 6:27,832,128...27,850,600
Ensembl chr 6:27,838,802...27,848,653
|
|
G |
Fkbpl |
FKBP prolyl isomerase like |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FKBPL mRNA |
CTD |
PMID:14503796 |
|
NCBI chr20:4,099,845...4,101,315
Ensembl chr20:4,099,806...4,101,368
|
|
G |
Flnc |
filamin C |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FLNC mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 4:58,034,088...58,061,882
Ensembl chr 4:58,034,189...58,061,844
|
|
G |
Flt3lg |
Fms related receptor tyrosine kinase 3 ligand |
affects expression |
ISO |
Cyclophosphamide affects the expression of FLT3L mRNA |
CTD |
PMID:12624490 |
|
NCBI chr 1:95,615,056...95,620,463
Ensembl chr 1:95,609,370...95,620,463
|
|
G |
Fndc3b |
fibronectin type III domain containing 3B |
affects response to substance |
ISO |
FNDC3B protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 2:110,311,439...110,617,504
Ensembl chr 2:110,312,694...110,547,830
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO EXP |
Capsaicin inhibits the reaction [Cyclophosphamide results in increased expression of FOS mRNA] alfuzosin inhibits the reaction [Cyclophosphamide results in increased expression of FOS protein]; Capsaicin inhibits the reaction [Cyclophosphamide results in increased expression of FOS protein]; resiniferatoxin inhibits the reaction [Cyclophosphamide results in increased expression of FOS protein] |
CTD |
PMID:7498375 PMID:8801120 PMID:8808730 PMID:9776515 PMID:10749792 PMID:15099680 PMID:15217452 PMID:17240043 PMID:18093676 More...
|
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Foxp3 |
forkhead box P3 |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of FOXP3 mRNA; Cyclophosphamide results in decreased expression of FOXP3 protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of FOXP3 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of FOXP3 protein] |
CTD |
PMID:15591121 PMID:32151603 |
|
NCBI chr X:14,908,494...14,924,994
Ensembl chr X:14,908,494...14,923,838
|
|
G |
Foxp4 |
forkhead box P4 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of FOXP4 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 9:13,058,506...13,115,406
Ensembl chr 9:13,058,476...13,114,879
|
|
G |
Fpr2 |
formyl peptide receptor 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FPR2 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 1:58,776,592...58,785,227
Ensembl chr 1:58,776,752...58,786,019
|
|
G |
Fscn1 |
fascin actin-bundling protein 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FSCN1 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr12:11,597,042...11,610,183
Ensembl chr12:11,597,048...11,610,211
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
increases expression decreases secretion multiple interactions |
ISO EXP |
Cyclophosphamide results in increased expression of FSHB protein Cyclophosphamide results in decreased secretion of FSHB protein Cilostazol inhibits the reaction [Cyclophosphamide results in increased expression of FSHB protein]; Melatonin inhibits the reaction [Cyclophosphamide results in increased expression of FSHB protein]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in decreased secretion of FSHB protein]; Valsartan inhibits the reaction [Cyclophosphamide results in decreased secretion of FSHB protein] |
CTD |
PMID:6788612 PMID:25446862 PMID:32197949 PMID:32456565 PMID:36154502 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Fshr |
follicle stimulating hormone receptor |
multiple interactions decreases expression |
ISO |
coenzyme Q10 inhibits the reaction [Cyclophosphamide results in decreased expression of FSHR mRNA] |
CTD |
PMID:31557371 |
|
NCBI chr 6:5,198,825...5,406,785
Ensembl chr 6:5,198,825...5,406,785
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FYN mRNA |
CTD |
PMID:17403535 |
|
NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
|
|
G |
G3bp1 |
G3BP stress granule assembly factor 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of G3BP1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr10:39,586,864...39,620,268
Ensembl chr10:39,586,864...39,620,268
|
|
G |
G6pc2 |
glucose-6-phosphatase catalytic subunit 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of G6PC2 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 3:53,999,821...54,005,539
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression affects expression |
EXP ISO |
Cyclophosphamide results in increased expression of GADD45A mRNA Cyclophosphamide affects the expression of GADD45A mRNA |
CTD |
PMID:18246545 PMID:29445054 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gal |
galanin and GMAP prepropeptide |
affects expression increases expression |
EXP ISO |
Cyclophosphamide affects the expression of GAL mRNA; Cyclophosphamide affects the expression of GAL protein Cyclophosphamide results in increased expression of GAL mRNA |
CTD |
PMID:16491427 PMID:17335920 PMID:18563302 |
|
NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959
|
|
G |
Galc |
galactosylceramidase |
affects response to substance |
ISO |
GALC protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 6:117,452,888...117,522,281
Ensembl chr 6:117,452,895...117,515,830
|
|
G |
Gamt |
guanidinoacetate N-methyltransferase |
multiple interactions |
ISO |
GAMT mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 7:9,448,590...9,451,413
Ensembl chr 7:9,448,628...9,451,778
|
|
G |
Gap43 |
growth associated protein 43 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of GAP43 protein |
CTD |
PMID:9486479 PMID:10536274 |
|
NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045
|
|
G |
Gas2 |
growth arrest-specific 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GAS2 protein |
CTD |
PMID:17475930 |
|
NCBI chr 1:101,452,361...101,582,619
Ensembl chr 1:101,482,591...101,582,619
|
|
G |
Gata3 |
GATA binding protein 3 |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of GATA3 mRNA; Cyclophosphamide results in decreased expression of GATA3 protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of GATA3 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of GATA3 protein] |
CTD |
PMID:21041162 PMID:32151603 |
|
NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391
|
|
G |
Gbp1 |
guanylate binding protein 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GBP1 mRNA |
CTD |
PMID:21621594 |
|
NCBI chr 2:231,398,136...231,432,773
Ensembl chr 2:231,398,163...231,432,131 Ensembl chr 2:231,398,163...231,432,131
|
|
G |
Gbp4 |
guanylate binding protein 4 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GBP3 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 2:231,304,910...231,318,883
Ensembl chr 2:231,305,244...231,318,879
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions decreases expression |
ISO |
Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of GCLC protein] Cyclophosphamide results in decreased expression of GCLC mRNA; Cyclophosphamide results in decreased expression of GCLC protein |
CTD |
PMID:27633142 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gdf9 |
growth differentiation factor 9 |
multiple interactions decreases expression |
ISO |
Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of GDF9 mRNA] |
CTD |
PMID:37863343 |
|
NCBI chr10:37,589,200...37,599,970
Ensembl chr10:37,595,679...37,599,672
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
increases expression |
EXP |
Cyclophosphamide results in increased expression of GDNF mRNA |
CTD |
PMID:10683293 |
|
NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Gem |
GTP binding protein overexpressed in skeletal muscle |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GEM mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 5:25,214,309...25,225,222
Ensembl chr 5:25,214,309...25,225,222
|
|
G |
Gfi1 |
growth factor independent 1 transcriptional repressor |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of GFI1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr14:2,040,576...2,056,874
Ensembl chr14:2,042,434...2,051,814
|
|
G |
Gfra1 |
GDNF family receptor alpha 1 |
multiple interactions |
ISO |
GFRA1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 1:257,315,682...257,552,004
Ensembl chr 1:257,321,742...257,551,473
|
|
G |
Gimap4 |
GTPase, IMAP family member 4 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of GIMAP4 mRNA |
CTD |
PMID:27466211 |
|
NCBI chr 4:77,636,401...77,643,315
Ensembl chr 4:77,636,401...77,643,306
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
affects expression multiple interactions decreases expression |
EXP ISO |
Cyclophosphamide affects the expression of GJA1 mRNA Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of GJA1 mRNA] |
CTD |
PMID:10859244 PMID:37863343 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gja4 |
gap junction protein, alpha 4 |
multiple interactions decreases expression |
ISO |
Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of GJA4 mRNA] |
CTD |
PMID:37863343 |
|
NCBI chr 5:139,633,324...139,635,857
Ensembl chr 5:139,633,287...139,635,925
|
|
G |
Gjb1 |
gap junction protein, beta 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of GJB1 mRNA |
CTD |
PMID:21621594 |
|
NCBI chr X:66,501,848...66,509,783
Ensembl chr X:66,501,820...66,509,925
|
|
G |
Glis1 |
GLIS family zinc finger 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of GLIS1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 5:122,222,155...122,412,141
Ensembl chr 5:122,222,128...122,412,141
|
|
G |
Glod4 |
glyoxalase domain containing 4 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of GLOD4 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr10:61,077,535...61,095,876
Ensembl chr10:61,066,421...61,095,898
|
|
G |
Glrb |
glycine receptor, beta |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GLRB mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 2:166,134,616...166,207,498
Ensembl chr 2:166,134,626...166,207,489
|
|
G |
Gls |
glutaminase |
increases expression affects response to substance |
ISO |
Cyclophosphamide results in increased expression of GLS mRNA GLS protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 PMID:21527772 |
|
NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900
|
|
G |
Gng12 |
G protein subunit gamma 12 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GNG12 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 4:96,011,118...96,134,767
Ensembl chr 4:96,010,952...96,134,712
|
|
G |
Gpatch8 |
G patch domain containing 8 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of GPATCH8 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr10:87,432,020...87,512,594
Ensembl chr10:87,433,266...87,512,419
|
|
G |
Gpr137b |
G protein-coupled receptor 137B |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GPR137B mRNA |
CTD |
PMID:21527772 |
|
NCBI chr17:86,003,635...86,041,841
Ensembl chr17:85,966,921...86,041,835
|
|
G |
Gpr18 |
G protein-coupled receptor 18 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of GPR18 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr15:98,997,427...99,001,177
Ensembl chr15:98,997,259...99,001,470
|
|
G |
Gpr20 |
G protein-coupled receptor 20 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GPR20 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 7:105,601,761...105,611,959
Ensembl chr 7:105,602,368...105,603,430
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases expression increases activity multiple interactions affects activity |
EXP ISO |
Cyclophosphamide results in increased expression of GPT protein Cyclophosphamide results in increased activity of GPT protein naringin affects the reaction [Cyclophosphamide affects the activity of GPT protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased activity of GPT protein]; Rutin inhibits the reaction [Cyclophosphamide results in increased activity of GPT protein]; Vitamin E inhibits the reaction [Cyclophosphamide results in increased expression of GPT protein] Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased activity of GPT protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased activity of GPT protein] |
CTD |
PMID:25753322 PMID:25779342 PMID:29753871 PMID:30506662 PMID:33992719 PMID:34748891 More...
|
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpt2 |
glutamic--pyruvic transaminase 2 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of GPT2 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr19:21,526,800...21,561,314
Ensembl chr19:21,517,621...21,560,610
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases expression multiple interactions decreases activity |
ISO EXP |
Cyclophosphamide results in decreased expression of GPX1 mRNA Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of GPX1 mRNA] Quercetin inhibits the reaction [Cyclophosphamide results in decreased activity of GPX1 protein] |
CTD |
PMID:23542512 PMID:35906875 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GPX3 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
increases expression multiple interactions decreases expression |
ISO |
Cyclophosphamide results in increased expression of GPX4 protein Dexrazoxane inhibits the reaction [Cyclophosphamide results in decreased expression of GPX4 protein] Cyclophosphamide promotes the reaction [Antimony results in decreased expression of and results in increased degradation of GPX4 protein] |
CTD |
PMID:17475930 PMID:37690746 PMID:38097005 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions decreases activity |
ISO EXP |
[[Cyclophosphamide co-treated with Cisplatin co-treated with Carmustine] results in decreased activity of GSR protein] which results in increased abundance of Glutathione Disulfide; [Cyclophosphamide co-treated with Cisplatin co-treated with Carmustine] results in decreased activity of GSR protein; Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of GSR protein]; Plant Extracts inhibits the reaction [Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of GSR protein]]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased activity of GSR protein] herbacetin inhibits the reaction [Cyclophosphamide results in decreased activity of GSR protein]; naringin inhibits the reaction [Cyclophosphamide results in decreased activity of GSR protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased activity of GSR protein]; Rutin inhibits the reaction [Cyclophosphamide results in decreased activity of GSR protein] |
CTD |
PMID:12114195 PMID:21772021 PMID:23542512 PMID:25446862 PMID:25753322 PMID:33992719 PMID:36198566 More...
|
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions decreases expression |
ISO EXP |
GSTA1 protein affects the metabolism of [Cyclophosphamide metabolite co-treated with Glutathione] Cyclophosphamide results in decreased expression of GSTA1 protein |
CTD |
PMID:12516103 PMID:15928459 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
multiple interactions |
ISO |
[GSTM1 protein co-treated with CYP2C9 protein] results in increased susceptibility to [Busulfan co-treated with Cyclophosphamide]; GSTM1 gene affects the susceptibility to [Carmustine co-treated with Cyclophosphamide co-treated with Cisplatin] |
CTD |
PMID:16087946 PMID:28744217 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of GSTM2 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions increases expression affects response to substance decreases response to substance |
ISO EXP |
GSTP1 gene SNP results in increased susceptibility to [Carmustine co-treated with Doxorubicin co-treated with Cyclophosphamide co-treated with Melphalan] Cyclophosphamide results in increased expression of GSTP1 mRNA; Cyclophosphamide results in increased expression of GSTP1 protein GSTP1 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]; Mesna inhibits the reaction [GSTP1 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]] GSTP1 protein affects the susceptibility to Cyclophosphamide GSTP1 protein results in decreased susceptibility to Cyclophosphamide |
CTD |
PMID:10954901 PMID:12791655 PMID:16141653 PMID:16242832 PMID:19696094 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gtf2b |
general transcription factor IIB |
increases expression |
EXP |
Cyclophosphamide results in increased expression of GTF2B mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 2:231,767,317...231,785,626
Ensembl chr 2:231,767,238...231,785,651
|
|
G |
Gtf3c1 |
general transcription factor IIIC subunit 1 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of GTF3C1 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 1:180,203,995...180,270,201
Ensembl chr 1:180,203,995...180,270,201
|
|
G |
Gusb |
glucuronidase, beta |
decreases expression multiple interactions increases activity |
EXP |
Cyclophosphamide results in decreased expression of GUSB protein Anthocyanins inhibits the reaction [Cyclophosphamide results in increased activity of GUSB protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased activity of GUSB protein] |
CTD |
PMID:17686619 PMID:25451569 |
|
NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905
|
|
G |
Gzma |
granzyme A |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of GZMA mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 2:44,740,569...44,752,502
Ensembl chr 2:44,740,569...44,752,493
|
|
G |
Gzmb |
granzyme B |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GZMB mRNA |
CTD |
PMID:15331540 |
|
NCBI chr15:30,343,352...30,346,814
Ensembl chr15:30,173,603...30,346,814
|
|
G |
H2ax |
H2A.X variant histone |
increases phosphorylation multiple interactions increases expression |
ISO EXP |
Cyclophosphamide results in increased phosphorylation of H2AX protein Dexrazoxane inhibits the reaction [Cyclophosphamide results in increased expression of H2AX protein] |
CTD |
PMID:32482060 PMID:33211169 PMID:34510228 PMID:37690746 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Has2 |
hyaluronan synthase 2 |
multiple interactions decreases expression |
ISO |
Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of HAS2 mRNA] |
CTD |
PMID:37863343 |
|
NCBI chr 7:88,113,326...88,139,337
Ensembl chr 7:88,113,326...88,128,933
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
increases expression multiple interactions |
EXP |
Cyclophosphamide results in increased expression of HAVCR1 protein herbacetin inhibits the reaction [Cyclophosphamide results in increased expression of HAVCR1 protein] |
CTD |
PMID:36198566 |
|
NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
multiple interactions decreases expression |
EXP |
O-1602 compound inhibits the reaction [Cyclophosphamide results in decreased expression of HBEGF protein] |
CTD |
PMID:32615180 |
|
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Hcrt |
hypocretin neuropeptide precursor |
affects localization decreases expression |
EXP |
Cyclophosphamide affects the localization of HCRT protein Cyclophosphamide results in decreased expression of HCRT mRNA |
CTD |
PMID:17881193 PMID:19666069 |
|
NCBI chr10:85,689,979...85,691,214
Ensembl chr10:85,689,465...85,691,210
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of HES1 protein SGI-1027 promotes the reaction [Cyclophosphamide results in decreased expression of HES1 protein]; Valproic Acid inhibits the reaction [Cyclophosphamide results in decreased expression of HES1 protein] |
CTD |
PMID:34658283 |
|
NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192
|
|
G |
Hes5 |
hes family bHLH transcription factor 5 |
multiple interactions |
ISO |
PAX5 protein affects the reaction [Cyclophosphamide results in decreased expression of HES5 protein] |
CTD |
PMID:34658283 |
|
NCBI chr 5:165,522,138...165,523,684
Ensembl chr 5:165,522,234...165,523,001
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression |
ISO |
Cyclophosphamide results in increased expression of HIF1A mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hinfp |
histone H4 transcription factor |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of HINFP mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 8:44,634,333...44,644,288
Ensembl chr 8:44,634,333...44,641,000
|
|
G |
Hm13 |
histocompatibility minor 13 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of H13 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 3:141,145,792...141,183,557
Ensembl chr 3:141,145,782...141,184,703
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
ISO |
Cyclophosphamide metabolite results in increased expression of HMGCS1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of HMGCS2 protein |
CTD |
PMID:15928459 |
|
NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
|
|
G |
Hmox1 |
heme oxygenase 1 |
affects expression increases expression multiple interactions decreases expression |
EXP ISO |
Cyclophosphamide affects the expression of HMOX1 mRNA Cyclophosphamide results in increased expression of HMOX1 mRNA; Cyclophosphamide results in increased expression of HMOX1 protein [astaxanthine co-treated with Cyclophosphamide] results in increased expression of HMOX1 protein; Cilostazol inhibits the reaction [Cyclophosphamide results in decreased expression of HMOX1 mRNA]; Cilostazol inhibits the reaction [Cyclophosphamide results in decreased expression of HMOX1 protein]; Hemin inhibits the reaction [Cyclophosphamide results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [Cyclophosphamide results in increased expression of HMOX1 mRNA]; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of HMOX1 protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of HMOX1 mRNA]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in decreased expression of HMOX1 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in decreased expression of HMOX1 protein] Cyclophosphamide results in decreased expression of HMOX1 mRNA; Cyclophosphamide results in decreased expression of HMOX1 protein |
CTD |
PMID:11906922 PMID:17979934 PMID:18206168 PMID:18246545 PMID:19952508 PMID:20038455 PMID:20433640 PMID:32197949 PMID:32456565 PMID:37419146 More...
|
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hmox2 |
heme oxygenase 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of HMOX2 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr10:10,797,076...10,831,178
Ensembl chr10:10,797,055...10,831,148
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
increases expression |
ISO EXP |
Cyclophosphamide results in increased expression of HNRNPK protein Cyclophosphamide results in increased expression of HNRNPK mRNA |
CTD |
PMID:11599041 PMID:17475930 |
|
NCBI chr17:6,262,936...6,275,001
Ensembl chr17:6,262,998...6,274,997
|
|
G |
Hoxa1 |
homeobox A1 |
affects response to substance |
ISO |
HOXA1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 4:81,255,814...81,258,587
Ensembl chr 4:81,255,883...81,258,504
|
|
G |
Hprt1 |
hypoxanthine phosphoribosyltransferase 1 |
increases mutagenesis |
ISO EXP |
Cyclophosphamide results in increased mutagenesis of HPRT1 gene |
CTD |
PMID:17116724 PMID:23677247 |
|
NCBI chr X:132,736,175...132,768,149
Ensembl chr X:132,736,096...132,768,154
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of HSP90AA1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha family class B member 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of HSP90AB1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
decreases expression increases expression |
EXP |
Cyclophosphamide results in decreased expression of HSP90B1 mRNA Cyclophosphamide results in increased expression of HSP90B1 mRNA |
CTD |
PMID:11599041 PMID:11906922 |
|
NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
affects expression increases expression |
EXP ISO |
Cyclophosphamide affects the expression of HSPA1A mRNA Cyclophosphamide results in increased expression of HSPA1A mRNA; Cyclophosphamide results in increased expression of HSPA1A protein |
CTD |
PMID:8917683 PMID:18246545 |
|
NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
affects expression decreases expression increases expression |
EXP ISO |
Cyclophosphamide affects the expression of HSPA1B mRNA Cyclophosphamide results in decreased expression of HSPA1B mRNA Cyclophosphamide metabolite results in increased expression of HSPA1B mRNA |
CTD |
PMID:16141653 PMID:18246545 PMID:24356939 |
|
NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240 Ensembl chr20:3,856,006...3,873,240
|
|
G |
Hspa2 |
heat shock protein family A (Hsp70) member 2 |
affects response to substance increases expression |
ISO EXP |
HSPA2 protein affects the susceptibility to Cyclophosphamide Cyclophosphamide results in increased expression of HSPA2 mRNA; Cyclophosphamide results in increased expression of HSPA2 protein |
CTD |
PMID:11599041 PMID:15928459 PMID:16217747 |
|
NCBI chr 6:95,128,504...95,131,281
Ensembl chr 6:95,128,350...95,131,287
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
decreases expression increases expression |
EXP ISO |
Cyclophosphamide results in decreased expression of HSPA5 mRNA Cyclophosphamide metabolite results in increased expression of HSPA5 mRNA |
CTD |
PMID:11906922 PMID:24356939 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
affects response to substance |
ISO |
HSPA8 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
|
|
G |
Hspa9 |
heat shock protein family A (Hsp70) member 9 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of HSPA9 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
decreases expression increases expression |
EXP |
Cyclophosphamide results in decreased expression of HSPB1 mRNA Cyclophosphamide results in increased expression of HSPB1 mRNA |
CTD |
PMID:11599041 PMID:11906922 PMID:18246545 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of HSPD1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662
|
|
G |
Hspe1 |
heat shock protein family E (Hsp10) member 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of HSPE1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 9:56,589,912...56,593,000
Ensembl chr 9:56,589,789...56,593,089
|
|
G |
Hsph1 |
heat shock protein family H (Hsp110) member 1 |
increases expression |
ISO |
Cyclophosphamide metabolite results in increased expression of HSPH1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224
|
|
G |
Hyls1 |
HYLS1, centriolar and ciliogenesis associated |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of HYLS1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 8:33,912,692...33,921,760
Ensembl chr 8:33,912,692...33,921,760
|
|
G |
Hyou1 |
hypoxia up-regulated 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of HYOU1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 8:44,706,073...44,718,189
Ensembl chr 8:44,706,263...44,718,186
|
|
G |
Ica1 |
islet cell autoantigen 1 |
affects response to substance |
ISO |
ICA1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:11751995 |
|
NCBI chr 4:36,656,475...36,804,705
Ensembl chr 4:36,656,475...36,804,298
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
affects response to substance multiple interactions |
ISO |
ICAM1 protein affects the susceptibility to Cyclophosphamide Cyclophosphamide inhibits the reaction [Paraquat results in increased expression of ICAM1 mRNA] |
CTD |
PMID:11591119 PMID:36031164 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of ID2 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase 1 |
increases expression |
ISO |
Cyclophosphamide metabolite results in increased expression of IDI1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
increases expression multiple interactions |
EXP |
Cyclophosphamide results in increased expression of IDO1 protein Cyclophosphamide results in increased expression of and results in increased activity of IDO1 protein; Quercetin inhibits the reaction [Cyclophosphamide results in increased activity of IDO1 protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of and results in increased activity of IDO1 protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of IDO1 protein] |
CTD |
PMID:34748891 PMID:35906875 |
|
NCBI chr16:67,430,654...67,442,726
Ensembl chr16:67,430,578...67,442,730
|
|
G |
Ier3 |
immediate early response 3 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of IER3 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583
|
|
G |
Ier5 |
immediate early response 5 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of IER5 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr13:67,270,134...67,272,226
Ensembl chr13:67,270,135...67,272,227
|
|
G |
Ifit2 |
interferon-induced protein with tetratricopeptide repeats 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of IFIT2 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 1:232,102,570...232,108,638
Ensembl chr 1:232,102,570...232,108,635
|
|
G |
Ifna1 |
interferon, alpha 1 |
increases expression multiple interactions |
EXP |
Cyclophosphamide results in increased expression of IFNA1 mRNA naringin inhibits the reaction [Cyclophosphamide results in increased expression of IFNA1 mRNA] |
CTD |
PMID:33992719 |
|
NCBI chr 5:103,097,356...103,097,925
Ensembl chr 5:103,097,356...103,097,925
|
|
G |
Ifng |
interferon gamma |
affects expression multiple interactions increases expression decreases expression decreases secretion |
ISO EXP |
Cyclophosphamide affects the expression of IFNG mRNA (4-formyl-9-methoxy-5-methyl-naphtho(2,3-b)furan-3-yl)methyl acetate inhibits the reaction [Cyclophosphamide results in decreased secretion of IFNG protein]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IFNG mRNA]; ganoderic acid C2 inhibits the reaction [Cyclophosphamide results in decreased expression of IFNG protein]; IFNG protein inhibits the reaction [Cyclophosphamide results in increased abundance of Nitric Oxide]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IFNG mRNA]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased secretion of IFNG protein] Cyclophosphamide results in increased expression of IFNG protein Cyclophosphamide results in decreased expression of IFNG mRNA; Cyclophosphamide results in decreased expression of IFNG protein Cyclophosphamide results in increased expression of IFNG mRNA [Cyclophosphamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of IFNG protein] |
CTD |
PMID:10607705 PMID:11006010 PMID:11014644 PMID:15331540 PMID:18848347 PMID:18957084 PMID:21068404 PMID:22842586 PMID:23395935 PMID:29594315 PMID:32151603 PMID:35906875 PMID:37853057 More...
|
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ifngr1 |
interferon gamma receptor 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of IFNGR1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:14,333,167...14,351,799
Ensembl chr 1:14,333,187...14,351,785
|
|
G |
Ifrd1 |
interferon-related developmental regulator 1 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of IFRD1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 6:57,269,395...57,317,833
Ensembl chr 6:57,269,384...57,288,990
|
|
G |
Igf2bp3 |
insulin-like growth factor 2 mRNA binding protein 3 |
affects response to substance |
ISO |
IGF2BP3 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 4:78,060,494...78,195,007
Ensembl chr 4:78,060,494...78,194,865
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
affects response to substance decreases expression |
ISO EXP |
IGFBP3 protein affects the susceptibility to Cyclophosphamide Cyclophosphamide results in decreased expression of IGFBP3 mRNA |
CTD |
PMID:16141653 PMID:16217747 |
|
NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
multiple interactions |
ISO |
IGFBP4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr10:83,995,253...84,007,272
Ensembl chr10:83,989,591...84,007,225
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of IGFBP5 mRNA |
CTD |
PMID:15331540 PMID:20849824 |
|
NCBI chr 9:74,452,371...74,464,953
Ensembl chr 9:74,448,382...74,465,156
|
|
G |
Ighg1 |
immunoglobulin heavy constant gamma 1 |
multiple interactions decreases expression |
ISO |
ganoderic acid C2 inhibits the reaction [Cyclophosphamide results in decreased expression of IGHG1 protein] |
CTD |
PMID:37853057 |
|
Ensembl chr 6:132,389,370...132,393,397
|
|
G |
Igkc |
immunoglobulin kappa constant |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of IGKC mRNA |
CTD |
PMID:15331540 |
|
|
|
G |
Il10 |
interleukin 10 |
decreases expression increases expression multiple interactions |
ISO EXP |
Cyclophosphamide results in decreased expression of IL10 mRNA Cyclophosphamide results in increased expression of IL10 protein Cyclophosphamide results in increased expression of IL10 mRNA Cyclophosphamide results in decreased expression of IL10 protein Anthocyanins inhibits the reaction [Cyclophosphamide results in decreased expression of IL10 protein]; chrysin inhibits the reaction [Cyclophosphamide results in increased expression of IL10 protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of IL10 protein] [Cyclophosphamide co-treated with Methotrexate co-treated with Fluorouracil] results in decreased expression of IL10 protein |
CTD |
PMID:11014644 PMID:11948286 PMID:18848347 PMID:21068404 PMID:25451569 PMID:31651976 PMID:37263553 More...
|
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12a |
interleukin 12A |
multiple interactions decreases expression |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] results in decreased expression of [IL12A protein binds to IL12B protein]; ganoderic acid C2 inhibits the reaction [Cyclophosphamide results in decreased expression of IL12A protein] |
CTD |
PMID:29228376 PMID:37853057 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il12b |
interleukin 12B |
affects expression increases expression multiple interactions decreases expression |
ISO |
Cyclophosphamide affects the expression of IL12B mRNA Cyclophosphamide results in increased expression of IL12B mRNA [Doxorubicin co-treated with Cyclophosphamide] results in decreased expression of [IL12A protein binds to IL12B protein]; ganoderic acid C2 inhibits the reaction [Cyclophosphamide results in decreased expression of IL12B protein] Cyclophosphamide inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL12B protein] |
CTD |
PMID:15331540 PMID:18957084 PMID:22842586 PMID:29228376 PMID:36416909 PMID:37853057 More...
|
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il13ra1 |
interleukin 13 receptor subunit alpha 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of IL13RA1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr X:115,348,822...115,408,682
Ensembl chr X:115,348,860...115,408,681 Ensembl chr11:115,348,860...115,408,681
|
|
G |
Il15 |
interleukin 15 |
multiple interactions decreases secretion |
ISO |
(4-formyl-9-methoxy-5-methyl-naphtho(2,3-b)furan-3-yl)methyl acetate inhibits the reaction [Cyclophosphamide results in decreased secretion of IL15 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased secretion of IL15 protein] |
CTD |
PMID:23395935 |
|
NCBI chr19:25,640,025...25,706,818
Ensembl chr19:25,640,251...25,706,820
|
|
G |
Il15ra |
interleukin 15 receptor subunit alpha |
increases expression |
ISO |
Cyclophosphamide results in increased expression of IL15RA mRNA |
CTD |
PMID:21041162 |
|
NCBI chr17:66,802,300...66,831,973
Ensembl chr17:66,802,334...66,832,278
|
|
G |
Il16 |
interleukin 16 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of IL16 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:137,617,702...137,718,022
Ensembl chr 1:137,617,944...137,718,130
|
|
G |
Il17a |
interleukin 17A |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of IL17A protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL17A protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL17A protein] |
CTD |
PMID:21880982 PMID:32151603 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il18 |
interleukin 18 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of IL18 protein |
CTD |
PMID:18848347 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression affects response to substance multiple interactions |
ISO EXP |
Cyclophosphamide results in increased expression of IL1A mRNA IL1A promoter polymorphism affects the susceptibility to Cyclophosphamide Cyclophosphamide results in increased expression of IL1A protein [Cyclophosphamide co-treated with Methotrexate co-treated with Fluorouracil] results in decreased expression of IL1A protein |
CTD |
PMID:15331540 PMID:16636934 PMID:18848347 PMID:31651976 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions increases response to substance decreases expression increases secretion |
ISO EXP |
Cyclophosphamide results in increased expression of IL1B mRNA; Cyclophosphamide results in increased expression of IL1B protein allyl sulfide inhibits the reaction [Cyclophosphamide results in increased secretion of IL1B protein]; Anthocyanins inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Bilirubin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B mRNA]; chrysin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Cilostazol inhibits the reaction [Cyclophosphamide results in increased expression of IL1B mRNA]; herbacetin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; naringin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B mRNA]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]]; O-1602 compound inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Pentoxifylline inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Rolipram inhibits the reaction [Cyclophosphamide results in increased expression of IL1B mRNA]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein] [Cyclophosphamide co-treated with Methotrexate co-treated with Fluorouracil] results in decreased expression of IL1B protein; [Doxorubicin co-treated with Cyclophosphamide] results in decreased expression of IL1B protein; Fenofibrate inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL1B protein]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL1B protein]; levocabastine inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; VIP protein inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein] IL1B protein results in increased susceptibility to Cyclophosphamide |
CTD |
PMID:8634684 PMID:11948286 PMID:15331540 PMID:18206168 PMID:18483878 PMID:18710439 PMID:18848347 PMID:20126887 PMID:23695977 PMID:25451569 PMID:29228376 PMID:29753871 PMID:30506662 PMID:31651976 PMID:31779506 PMID:32151603 PMID:32456565 PMID:32615180 PMID:33992719 PMID:35762198 PMID:36198566 PMID:37263553 PMID:38278497 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
increases expression multiple interactions |
EXP |
Cyclophosphamide results in increased expression of IL1R1 mRNA naringin inhibits the reaction [Cyclophosphamide results in increased expression of IL1R1 mRNA] |
CTD |
PMID:33992719 |
|
NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
increases expression |
ISO |
Cyclophosphamide results in increased expression of IL1RN mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445
|
|
G |
Il2 |
interleukin 2 |
increases expression decreases expression multiple interactions decreases secretion |
ISO EXP |
Cyclophosphamide results in increased expression of IL2 mRNA Cyclophosphamide results in decreased expression of IL2 protein (4-formyl-9-methoxy-5-methyl-naphtho(2,3-b)furan-3-yl)methyl acetate inhibits the reaction [Cyclophosphamide results in decreased secretion of IL2 protein]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL2 mRNA]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL2 mRNA]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased secretion of IL2 protein] |
CTD |
PMID:11006010 PMID:11948286 PMID:18848347 PMID:23395935 PMID:32151603 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il21 |
interleukin 21 |
multiple interactions decreases expression |
ISO |
Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL21 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL21 protein] |
CTD |
PMID:32151603 |
|
NCBI chr 2:120,117,105...120,127,012
Ensembl chr 2:120,119,444...120,126,996
|
|
G |
Il23a |
interleukin 23 subunit alpha |
decreases secretion multiple interactions decreases expression |
ISO |
Cyclophosphamide results in decreased secretion of IL23A protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL23A protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL23A protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased secretion of IL23A protein] |
CTD |
PMID:23395935 PMID:32151603 |
|
NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923
|
|
G |
Il3 |
interleukin 3 |
multiple interactions |
ISO |
[Cyclophosphamide co-treated with Methotrexate co-treated with Fluorouracil] results in decreased expression of IL3 protein |
CTD |
PMID:31651976 |
|
NCBI chr10:38,405,716...38,408,066
Ensembl chr10:38,405,716...38,408,066
|
|
G |
Il4 |
interleukin 4 |
decreases expression increases expression multiple interactions |
ISO EXP |
Cyclophosphamide results in decreased expression of IL4 mRNA; Cyclophosphamide results in decreased expression of IL4 protein Cyclophosphamide results in increased expression of IL4 mRNA; Cyclophosphamide results in increased expression of IL4 protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL4 protein]; ganoderic acid C2 inhibits the reaction [Cyclophosphamide results in decreased expression of IL4 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL4 protein] |
CTD |
PMID:11006010 PMID:11014644 PMID:11948286 PMID:18848347 PMID:22842586 PMID:32151603 PMID:37853057 More...
|
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
increases expression |
ISO EXP |
Cyclophosphamide results in increased expression of IL5 mRNA; Cyclophosphamide results in increased expression of IL5 protein |
CTD |
PMID:11006010 PMID:18848347 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression decreases secretion increases secretion |
ISO EXP |
[Cyclophosphamide co-treated with Dexamethasone] inhibits the reaction [Paraquat results in increased expression of IL6 mRNA]; [Doxorubicin co-treated with Cyclophosphamide] results in decreased expression of IL6 protein; Fenofibrate inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased secretion of IL6 protein]; levocabastine inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Sizofiran promotes the reaction [Cyclophosphamide results in increased expression of IL6 mRNA]; Sizofiran promotes the reaction [Cyclophosphamide results in increased expression of IL6 protein] allyl sulfide inhibits the reaction [Cyclophosphamide results in increased secretion of IL6 protein]; chrysin inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Cilostazol inhibits the reaction [Cyclophosphamide results in increased expression of IL6 mRNA]; herbacetin inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; O-1602 compound inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Pentoxifylline inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Rutin inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein] Cyclophosphamide results in increased expression of IL6 mRNA; Cyclophosphamide results in increased expression of IL6 protein |
CTD |
PMID:10052129 PMID:11948286 PMID:17010015 PMID:18848347 PMID:20126887 PMID:21068404 PMID:22842586 PMID:23395935 PMID:23695977 PMID:25753322 PMID:29228376 PMID:30506662 PMID:31779506 PMID:32456565 PMID:32615180 PMID:34748891 PMID:35906875 PMID:36031164 PMID:36198566 PMID:37263553 PMID:38278497 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ilf3 |
interleukin enhancer binding factor 3 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of ILF3 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 8:19,922,409...19,960,495
Ensembl chr 8:19,922,460...19,960,350
|
|
G |
Irag2 |
inositol 1,4,5-triphosphate receptor associated 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of IRAG2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 4:178,088,902...178,143,569
Ensembl chr 4:178,088,507...178,143,557
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of IRS1 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Isg15 |
ISG15 ubiquitin-like modifier |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ISG15 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 5:166,784,148...166,785,435
Ensembl chr 5:166,784,148...166,785,435
|
|
G |
Isl2 |
ISL LIM homeobox 2 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of ISL2 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 8:55,923,805...55,928,790
Ensembl chr 8:55,923,805...55,928,790
|
|
G |
Itk |
IL2-inducible T-cell kinase |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ITK mRNA |
CTD |
PMID:21041162 |
|
NCBI chr10:30,753,344...30,814,685
Ensembl chr10:30,753,344...30,814,685
|
|
G |
Jag1 |
jagged canonical Notch ligand 1 |
multiple interactions decreases expression |
ISO |
PAX5 protein affects the reaction [Cyclophosphamide results in decreased expression of JAG1 protein]; SGI-1027 promotes the reaction [Cyclophosphamide results in decreased expression of JAG1 protein]; Valproic Acid inhibits the reaction [Cyclophosphamide results in decreased expression of JAG1 protein] |
CTD |
PMID:34658283 |
|
NCBI chr 3:124,406,783...124,442,220
Ensembl chr 3:124,406,794...124,442,209
|
|
G |
Jchain |
joining chain of multimeric IgA and IgM |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of JCHAIN mRNA |
CTD |
PMID:15331540 |
|
NCBI chr14:19,538,927...19,547,023
Ensembl chr14:19,538,952...19,546,298
|
|
G |
Kbtbd11 |
kelch repeat and BTB domain containing 11 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of KBTBD11 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr16:74,618,291...74,638,010
Ensembl chr16:74,615,792...74,637,736
|
|
G |
Kcnq4 |
potassium voltage-gated channel subfamily Q member 4 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of KCNQ4 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 5:134,275,145...134,326,992
Ensembl chr 5:134,275,934...134,326,932
|
|
G |
Kdm1a |
lysine demethylase 1A |
multiple interactions increases expression |
ISO |
Cyclophosphamide promotes the reaction [KDM1A protein results in decreased methylation of and results in decreased degradation of DNMT1 protein] Cyclophosphamide results in increased expression of KDM1A protein |
CTD |
PMID:22007908 |
|
NCBI chr 5:148,782,976...148,838,319
Ensembl chr 5:148,782,976...148,838,319
|
|
G |
Kdm2a |
lysine demethylase 2A |
increases expression |
EXP |
Cyclophosphamide results in increased expression of KDM2A mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 1:201,612,427...201,682,359
Ensembl chr 1:201,612,453...201,680,787
|
|
G |
Kdm4b |
lysine demethylase 4B |
multiple interactions |
ISO |
KDM4B mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 9:1,158,737...1,237,233
Ensembl chr 9:1,158,752...1,236,543
|
|
G |
Kdr |
kinase insert domain receptor |
decreases expression increases expression |
EXP |
Cyclophosphamide results in decreased expression of KDR mRNA; Cyclophosphamide results in decreased expression of KDR protein Cyclophosphamide results in increased expression of KDR mRNA |
CTD |
PMID:18632792 PMID:19701751 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions decreases expression |
EXP |
Quercetin inhibits the reaction [Cyclophosphamide results in decreased expression of KEAP1 mRNA] |
CTD |
PMID:37419146 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Kif21b |
kinesin family member 21B |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of KIF21B mRNA |
CTD |
PMID:24356939 |
|
NCBI chr13:47,576,129...47,626,112
Ensembl chr13:47,576,160...47,626,127
|
|
G |
Kif3a |
kinesin family member 3a |
multiple interactions |
ISO |
KIF3A mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr10:37,725,930...37,761,183
Ensembl chr10:37,725,970...37,759,191
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of KIT protein [dorsomorphin co-treated with Cyclophosphamide] results in decreased expression of KIT protein; asperuloside inhibits the reaction [[dorsomorphin co-treated with Cyclophosphamide] results in decreased expression of KIT protein]; asperuloside inhibits the reaction [Cyclophosphamide results in decreased expression of KIT protein]; CSF2 protein inhibits the reaction [Cyclophosphamide results in decreased expression of KIT protein] |
CTD |
PMID:38348709 |
|
NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
|
|
G |
Kitlg |
KIT ligand |
affects expression multiple interactions increases expression |
ISO |
Cyclophosphamide affects the expression of KITL mRNA [Cyclophosphamide co-treated with Sizofiran] results in increased expression of KITL mRNA Cyclophosphamide results in increased expression of KITL mRNA |
CTD |
PMID:10052129 PMID:12624490 PMID:12662436 |
|
NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214
|
|
G |
Klf13 |
KLF transcription factor 13 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of KLF13 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:117,505,857...117,536,626
Ensembl chr 1:117,503,602...117,551,227
|
|
G |
Klf2 |
KLF transcription factor 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of KLF2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr16:17,521,107...17,523,739
Ensembl chr16:17,514,552...17,523,944
|
|
G |
Klf4 |
KLF transcription factor 4 |
decreases response to substance |
ISO |
KLF4 results in decreased susceptibility to Cyclophosphamide |
CTD |
PMID:21833590 |
|
NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
|
|
G |
Klf5 |
KLF transcription factor 5 |
affects response to substance |
ISO |
KLF5 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445
|
|
G |
Krcc1 |
lysine-rich coiled-coil 1 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of KRCC1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 4:103,261,642...103,274,672
Ensembl chr 4:103,261,536...103,277,156
|
|
G |
Krt8 |
keratin 8 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of KRT8 mRNA |
CTD |
PMID:21621594 |
|
NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728
|
|
G |
Krt80 |
keratin 80 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of KRT80 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 7:132,463,216...132,485,134
Ensembl chr 7:132,463,218...132,485,508
|
|
G |
Lama5 |
laminin subunit alpha 5 |
increases expression multiple interactions |
ISO |
Cyclophosphamide results in increased expression of LAMA5 mRNA 5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline inhibits the reaction [Cyclophosphamide results in increased expression of LAMA5 mRNA] |
CTD |
PMID:30760223 |
|
NCBI chr 3:167,270,296...167,318,370
Ensembl chr 3:167,270,296...167,318,451
|
|
G |
Lamc2 |
laminin subunit gamma 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of LAMC2 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr13:65,284,664...65,344,164
Ensembl chr13:65,284,664...65,344,200
|
|
G |
Lasp1 |
LIM and SH3 protein 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of LASP1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr10:82,795,177...82,835,659
Ensembl chr10:82,795,137...82,943,292
|
|
G |
Lat |
linker for activation of T cells |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of LAT mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:180,936,536...180,941,561
Ensembl chr 1:180,936,534...180,941,578
|
|
G |
Lats1 |
large tumor suppressor kinase 1 |
multiple interactions |
EXP |
Cyclophosphamide results in decreased expression of and results in increased phosphorylation of LATS1 protein; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of and results in increased phosphorylation of LATS1 protein] |
CTD |
PMID:36154502 |
|
NCBI chr 1:2,160,411...2,193,640
Ensembl chr 1:2,160,411...2,193,640
|
|
G |
Lck |
LCK proto-oncogene, Src family tyrosine kinase |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of LCK mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 5:141,888,318...141,916,945
Ensembl chr 5:141,888,326...141,903,794
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression multiple interactions |
ISO EXP |
Cyclophosphamide results in increased expression of LCN2 mRNA [Cyclophosphamide co-treated with Mecamylamine] results in increased expression of LCN2 mRNA Cyclophosphamide results in increased expression of LCN2 mRNA; Cyclophosphamide results in increased expression of LCN2 protein herbacetin inhibits the reaction [Cyclophosphamide results in increased expression of LCN2 protein] |
CTD |
PMID:15331540 PMID:18433785 PMID:20623750 PMID:36198566 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Ldhb |
lactate dehydrogenase B |
affects response to substance |
ISO |
LDHB protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 4:175,428,382...175,446,403
Ensembl chr 4:175,428,385...175,446,403
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of LEF1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794
|
|
G |
Lgals1 |
galectin 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of LGALS1 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 7:110,485,239...110,488,345
Ensembl chr 7:110,481,392...110,488,345
|
|
G |
Lgals7 |
galectin 7 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of LGALS7 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:84,148,612...84,152,016
Ensembl chr 1:84,150,252...84,152,015
|
|
G |
Lhb |
luteinizing hormone subunit beta |
decreases secretion multiple interactions increases expression |
EXP |
Cyclophosphamide results in decreased secretion of LHB protein Cilostazol inhibits the reaction [Cyclophosphamide results in increased expression of LHB protein]; Melatonin inhibits the reaction [Cyclophosphamide results in increased expression of LHB protein]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in decreased secretion of LHB protein]; Valsartan inhibits the reaction [Cyclophosphamide results in decreased secretion of LHB protein] |
CTD |
PMID:25446862 PMID:32197949 PMID:32456565 PMID:36154502 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lhx2 |
LIM homeobox 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of LHX2 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 3:22,113,619...22,143,909
Ensembl chr 3:22,126,007...22,143,908
|
|
G |
Limd1 |
LIM domain containing 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of LIMD1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 8:123,121,363...123,168,476
Ensembl chr 8:123,122,460...123,167,714
|
|
G |
Lmcd1 |
LIM and cysteine-rich domains 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of LMCD1 mRNA |
CTD |
PMID:23558518 |
|
NCBI chr 4:145,393,153...145,452,049
Ensembl chr 4:145,393,145...145,452,046
|
|
G |
Lmnb1 |
lamin B1 |
multiple interactions |
ISO |
[Cladribine co-treated with Cyclophosphamide co-treated with Mitoxantrone] results in decreased expression of LMNB1 protein; [Cladribine co-treated with Cyclophosphamide] results in decreased expression of LMNB1 protein |
CTD |
PMID:15582267 |
|
NCBI chr18:50,175,861...50,215,210
Ensembl chr18:50,175,874...50,214,502
|
|
G |
Lonrf2 |
LON peptidase N-terminal domain and ring finger 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of LONRF2 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 9:41,033,125...41,070,551
Ensembl chr 9:41,034,628...41,070,649
|
|
G |
Lsg1 |
large 60S subunit nuclear export GTPase 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of LSG1 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr11:70,132,919...70,168,526
Ensembl chr11:70,143,847...70,168,518
|
|
G |
Ltbr |
lymphotoxin beta receptor |
increases expression |
ISO |
Cyclophosphamide results in increased expression of LTBR mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 4:158,108,884...158,115,339
Ensembl chr 4:158,108,886...158,121,539
|
|
G |
Ltf |
lactotransferrin |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of LTF mRNA |
CTD |
PMID:21621594 |
|
NCBI chr 8:110,999,948...111,022,795
Ensembl chr 8:110,999,948...111,022,795
|
|
G |
Ly6a |
lymphocyte antigen 6 family member A |
increases expression |
ISO |
Cyclophosphamide results in increased expression of LY6A mRNA |
CTD |
PMID:15331540 PMID:21041162 |
|
NCBI chr 7:107,177,191...107,189,436
Ensembl chr 7:107,183,469...107,189,981
|
|
G |
Maged1 |
MAGE family member D1 |
affects response to substance |
ISO |
MAGED1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr X:59,422,715...59,429,381
Ensembl chr X:59,422,717...59,429,364
|
|
G |
Man2b2 |
mannosidase, alpha, class 2B, member 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MAN2B2 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr14:73,969,079...73,994,089
Ensembl chr14:73,969,003...74,004,281
|
|
G |
Maoa |
monoamine oxidase A |
increases expression |
ISO |
Cyclophosphamide results in increased expression of MAOA mRNA |
CTD |
PMID:17403535 |
|
NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions increases lipidation |
ISO |
asperuloside promotes the reaction [Cyclophosphamide results in increased lipidation of MAP1LC3B protein]; CSF2 protein promotes the reaction [Cyclophosphamide results in increased lipidation of MAP1LC3B protein]; dorsomorphin inhibits the reaction [asperuloside promotes the reaction [Cyclophosphamide results in increased lipidation of MAP1LC3B protein]]; dorsomorphin inhibits the reaction [Cyclophosphamide results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:38348709 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Map3k12 |
mitogen activated protein kinase kinase kinase 12 |
affects expression |
EXP |
Cyclophosphamide affects the expression of MAP3K12 mRNA |
CTD |
PMID:18246545 |
|
NCBI chr 7:133,630,267...133,648,464
Ensembl chr 7:133,630,835...133,640,789
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation increases expression multiple interactions |
ISO EXP |
Cyclophosphamide results in increased phosphorylation of MAPK1 protein Cyclophosphamide results in increased expression of MAPK1 mRNA; Cyclophosphamide results in increased expression of MAPK1 protein modified form Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:11599041 PMID:15733095 PMID:17110531 PMID:17409261 PMID:19638304 PMID:19696094 PMID:19996110 More...
|
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions affects expression decreases expression increases expression |
ISO EXP |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of MAPK14 mRNA Cyclophosphamide affects the expression of MAPK14 mRNA Cyclophosphamide results in decreased expression of MAPK14 mRNA chrysin inhibits the reaction [Cyclophosphamide results in increased expression of MAPK14 protein] |
CTD |
PMID:16322899 PMID:18246545 PMID:37263553 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases expression increases phosphorylation multiple interactions |
EXP ISO |
Cyclophosphamide results in increased expression of MAPK3 protein modified form Cyclophosphamide results in increased phosphorylation of MAPK3 protein Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:15733095 PMID:17110531 PMID:17409261 PMID:19638304 PMID:19696094 PMID:19996110 More...
|
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk7 |
mitogen-activated protein kinase 7 |
multiple interactions |
EXP |
Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK7 protein |
CTD |
PMID:17110531 |
|
NCBI chr10:46,170,264...46,176,262
Ensembl chr10:46,170,167...46,176,267
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation multiple interactions |
ISO EXP |
Cyclophosphamide results in increased phosphorylation of MAPK8 protein GSTP1 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]; GSTP2 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]; Mesna inhibits the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]; Mesna inhibits the reaction [GSTP1 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]]; Mesna inhibits the reaction [GSTP2 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]] Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK8 protein; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK8 protein] |
CTD |
PMID:19696094 PMID:19996110 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK9 protein; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK9 protein] |
CTD |
PMID:19996110 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
ISO |
MAPT mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Marchf7 |
membrane associated ring-CH-type finger 7 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MARCHF7 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 3:44,680,229...44,720,172
Ensembl chr 3:44,681,632...44,720,168
|
|
G |
Marcks |
myristoylated alanine rich protein kinase C substrate |
increases expression |
ISO |
Cyclophosphamide results in increased expression of MARCKS mRNA |
CTD |
PMID:17403535 |
|
NCBI chr20:40,685,315...40,691,012
Ensembl chr20:40,685,315...40,691,012
|
|
G |
Mcm5 |
minichromosome maintenance complex component 5 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of MCM5 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr19:13,483,030...13,504,389
Ensembl chr19:13,483,066...13,504,389
|
|
G |
Mdfic |
MyoD family inhibitor domain containing |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of MDFIC mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 4:43,972,310...44,052,162
Ensembl chr 4:43,972,507...44,052,161
|
|
G |
Med13l |
mediator complex subunit 13L |
multiple interactions |
ISO |
MED13L mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr12:37,807,596...38,004,886
Ensembl chr12:37,808,285...38,004,473
|
|
G |
Melk |
maternal embryonic leucine zipper kinase |
multiple interactions |
ISO |
MELK mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 5:58,540,393...58,600,562
Ensembl chr 5:58,540,449...58,600,937
|
|
G |
Metrn |
meteorin, glial cell differentiation regulator |
multiple interactions |
ISO |
METRN mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr10:14,816,684...14,818,702
Ensembl chr10:14,816,572...14,818,701
|
|
G |
Mfge8 |
milk fat globule EGF and factor V/VIII domain containing |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of MFGE8 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 1:133,064,665...133,080,069
Ensembl chr 1:133,064,665...133,080,073
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
decreases expression decreases response to substance |
ISO |
Cyclophosphamide results in decreased expression of MGMT mRNA MGMT protein results in decreased susceptibility to Cyclophosphamide |
CTD |
PMID:15741301 PMID:17403535 |
|
NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MGST1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Mif |
macrophage migration inhibitory factor |
multiple interactions |
EXP |
Cyclophosphamide affects the localization of and affects the expression of MIF protein; Cyclophosphamide promotes the reaction [MIF protein binds to CXCR4 protein] |
CTD |
PMID:19066630 |
|
NCBI chr20:12,790,919...12,791,784
Ensembl chr20:12,790,902...12,799,504
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression multiple interactions increases expression |
ISO EXP |
Cyclophosphamide results in decreased expression of MKI67 protein Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of MKI67 protein] Cyclophosphamide results in increased expression of MKI67 protein |
CTD |
PMID:33737021 PMID:36154502 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mlh1 |
mutL homolog 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MLH1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 8:111,196,468...111,233,721
Ensembl chr 8:111,196,468...111,233,617
|
|
G |
Mllt11 |
MLLT11, transcription factor 7 cofactor |
decreases response to substance |
ISO |
MLLT11 protein results in decreased susceptibility to Cyclophosphamide |
CTD |
PMID:31587870 |
|
NCBI chr 2:182,795,790...182,804,960
Ensembl chr 2:182,795,790...182,797,199
|
|
G |
Mmel1 |
membrane metallo-endopeptidase-like 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of MMEL1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 5:165,431,278...165,461,716
Ensembl chr 5:165,431,343...165,461,716
|
|
G |
Mmp11 |
matrix metallopeptidase 11 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MMP11 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr20:12,730,846...12,739,629
Ensembl chr20:12,730,836...12,739,628
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of MMP3 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Mmp8 |
matrix metallopeptidase 8 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of MMP8 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 8:4,724,009...4,733,864
Ensembl chr 8:4,724,029...4,733,520
|
|
G |
Mnda |
myeloid cell nuclear differentiation antigen |
increases expression |
ISO |
Cyclophosphamide results in increased expression of IFI204 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr13:86,017,888...86,035,556
Ensembl chr13:86,017,892...86,034,201
|
|
G |
Mpc2 |
mitochondrial pyruvate carrier 2 |
affects response to substance |
ISO |
MPC2 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr13:77,728,176...77,747,664
Ensembl chr13:77,728,250...77,747,664
|
|
G |
Mpg |
N-methylpurine-DNA glycosylase |
affects expression |
EXP |
Cyclophosphamide affects the expression of MPG mRNA |
CTD |
PMID:11906922 |
|
NCBI chr10:15,396,246...15,402,528
Ensembl chr10:15,395,782...15,402,520
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions increases activity |
EXP |
Anthocyanins inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein]; Hemin inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein]; Rolipram inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein] |
CTD |
PMID:10749792 PMID:17979934 PMID:18710439 PMID:25451569 PMID:34748891 PMID:35906875 More...
|
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mr1 |
major histocompatibility complex, class I-related |
increases expression |
ISO |
Cyclophosphamide results in increased expression of MR1 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr13:67,298,362...67,317,985
Ensembl chr13:67,299,585...67,317,970
|
|
G |
Ms4a3 |
membrane spanning 4-domains A3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of MS4A3 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 1:208,462,300...208,480,129
Ensembl chr 1:208,462,301...208,480,101
|
|
G |
Msh2 |
mutS homolog 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MSH2 mRNA |
CTD |
PMID:11056294 PMID:11906922 |
|
NCBI chr 6:6,813,793...6,872,960
Ensembl chr 6:6,813,795...6,872,938
|
|
G |
Msh3 |
mutS homolog 3 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MSH3 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 2:23,444,326...23,585,777
|
|
G |
Mss51 |
MSS51 mitochondrial translational activator |
increases expression |
EXP |
Cyclophosphamide results in increased expression of MSS51 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr15:3,805,240...3,819,385
Ensembl chr15:3,807,516...3,819,385
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of MTHFD2 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions increases phosphorylation |
ISO |
asperuloside inhibits the reaction [Cyclophosphamide results in increased phosphorylation of MTOR protein]; asperuloside inhibits the reaction [dorsomorphin promotes the reaction [Cyclophosphamide results in increased phosphorylation of MTOR protein]]; CSF2 protein inhibits the reaction [Cyclophosphamide results in increased phosphorylation of MTOR protein]; dorsomorphin inhibits the reaction [Cyclophosphamide results in increased phosphorylation of MTOR protein]; dorsomorphin promotes the reaction [Cyclophosphamide results in increased phosphorylation of MTOR protein] |
CTD |
PMID:38348709 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Mtr |
5-methyltetrahydrofolate-homocysteine methyltransferase |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MTR mRNA |
CTD |
PMID:27281708 |
|
NCBI chr17:58,219,998...58,308,560
Ensembl chr17:58,220,071...58,304,822
|
|
G |
Muc13 |
mucin 13, cell surface associated |
increases expression |
ISO |
Cyclophosphamide results in increased expression of MUC13 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr11:66,957,208...66,980,264
Ensembl chr11:66,960,595...66,984,727
|
|
G |
Mx2 |
MX dynamin like GTPase 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of MX2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr11:36,905,698...36,936,308
Ensembl chr11:36,906,111...36,930,342
|
|
G |
Mxi1 |
MAX interactor 1, dimerization protein |
affects response to substance |
ISO |
MXI1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 1:252,323,915...252,383,682
Ensembl chr 1:252,323,303...252,383,681
|
|
G |
Myh10 |
myosin heavy chain 10 |
affects response to substance |
ISO |
MYH10 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr10:53,393,901...53,525,174
Ensembl chr10:53,394,389...53,525,165
|
|
G |
Naip6 |
NLR family, apoptosis inhibitory protein 6 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of NAIP mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 2:31,507,423...31,559,098
Ensembl chr 2:31,507,424...31,570,542
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NAMPT mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
|
|
G |
Nanos1 |
nanos C2HC-type zinc finger 1 |
increases expression |
ISO |
Cyclophosphamide metabolite results in increased expression of NANOS1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 1:259,897,663...259,901,561
Ensembl chr 1:259,897,939...259,898,730
|
|
G |
Nasp |
nuclear autoantigenic sperm protein |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NASP mRNA |
CTD |
PMID:16141653 |
|
NCBI chr 5:130,057,363...130,083,003
Ensembl chr 5:130,057,363...130,082,928
|
|
G |
Ncoa7 |
nuclear receptor coactivator 7 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of NCOA7 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 1:26,856,228...27,016,950
Ensembl chr 1:26,856,530...27,015,871
|
|
G |
Ndufs2 |
NADH:ubiquinone oxidoreductase core subunit S2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of NDUFS2 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr13:83,654,402...83,671,474
Ensembl chr13:83,654,406...83,671,420
|
|
G |
Neto2 |
neuropilin and tolloid like 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NETO2 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr19:21,344,299...21,415,524
Ensembl chr19:21,344,289...21,417,023
|
|
G |
Nfatc3 |
nuclear factor of activated T-cells 3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of NFATC3 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr19:33,960,643...34,035,150
Ensembl chr19:33,960,852...34,035,150
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions decreases expression increases expression increases response to substance |
EXP ISO |
[astaxanthine co-treated with Cyclophosphamide] results in increased expression of NFE2L2 protein; [Rutin co-treated with Chitosan] inhibits the reaction [Cyclophosphamide results in decreased expression of NFE2L2 mRNA]; Cilostazol inhibits the reaction [Cyclophosphamide results in decreased expression of NFE2L2 mRNA]; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of NFE2L2 protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of NFE2L2 mRNA] Cyclophosphamide results in decreased expression of NFE2L2 mRNA; Cyclophosphamide results in decreased expression of NFE2L2 protein Cyclophosphamide results in increased expression of NFE2L2 mRNA; Cyclophosphamide results in increased expression of NFE2L2 protein NFE2L2 gene mutant form results in increased susceptibility to Cyclophosphamide Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of CAT protein]; Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of GCLC protein]; Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of NQO1 protein]; NFE2L2 gene mutant form inhibits the reaction [Cyclophosphamide results in increased expression of NQO1 mRNA]; NFE2L2 gene mutant form promotes the reaction [Cyclophosphamide results in decreased expression of CAT protein]; NFE2L2 gene mutant form promotes the reaction [Cyclophosphamide results in decreased expression of NQO1 protein] |
CTD |
PMID:20038455 PMID:20433640 PMID:27633142 PMID:32456565 PMID:37419146 PMID:38211767 More...
|
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfe2l3 |
NFE2 like bZIP transcription factor 3 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of NFE2L3 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 4:80,506,756...80,534,629
Ensembl chr 4:80,506,756...80,534,629
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases phosphorylation multiple interactions |
ISO |
Cyclophosphamide results in increased phosphorylation of NFKBIA protein ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:30506662 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nfkbiz |
NFKB inhibitor zeta |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NFKBIZ mRNA |
CTD |
PMID:15331540 |
|
NCBI chr11:44,782,676...44,810,722
Ensembl chr11:44,782,676...44,810,723
|
|
G |
Ngf |
nerve growth factor |
multiple interactions increases expression decreases expression |
ISO EXP |
3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazoleacetic acid methyl ester inhibits the reaction [Cyclophosphamide results in increased expression of NGF protein]; Cyclophosphamide promotes the reaction [NGF results in increased expression of VEGFA mRNA]; VIP protein affects the reaction [Cyclophosphamide results in increased expression of NGF protein] Cyclophosphamide results in decreased expression of NGF protein Cyclophosphamide results in increased expression of NGF mRNA; Cyclophosphamide results in increased expression of NGF protein NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of AKT1 protein]; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK8 protein]; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK9 protein]; O-1602 compound inhibits the reaction [Cyclophosphamide results in increased expression of NGF protein]; rofecoxib inhibits the reaction [Cyclophosphamide results in increased expression of NGF protein] |
CTD |
PMID:10683293 PMID:16879691 PMID:18299998 PMID:18632792 PMID:19996110 PMID:20127836 PMID:32615180 More...
|
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Ngfr |
nerve growth factor receptor |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NGFR mRNA; Cyclophosphamide results in increased expression of NGFR protein |
CTD |
PMID:8817519 PMID:18189308 PMID:18842820 |
|
NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518
|
|
G |
Nid1 |
nidogen 1 |
affects response to substance |
ISO |
NID1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr17:86,085,133...86,158,272
Ensembl chr17:86,085,077...86,158,267
|
|
G |
Nkain1 |
Sodium/potassium transporting ATPase interacting 1 |
multiple interactions |
ISO |
NKAIN1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 5:142,747,702...142,792,665
Ensembl chr 5:142,747,505...142,791,863
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions increases expression |
EXP ISO |
Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of NLRP3 protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of NLRP3 protein] Fenofibrate inhibits the reaction [Cyclophosphamide results in increased expression of NLRP3 protein]; levocabastine inhibits the reaction [Cyclophosphamide results in increased expression of NLRP3 protein] |
CTD |
PMID:35762198 PMID:38278497 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nme1 |
NME/NM23 nucleoside diphosphate kinase 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NME1 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr10:78,907,036...78,929,659
Ensembl chr10:78,906,083...78,916,408
|
|
G |
Nos1 |
nitric oxide synthase 1 |
increases expression decreases expression multiple interactions |
EXP |
Cyclophosphamide results in increased expression of NOS1 protein Cyclophosphamide results in decreased expression of NOS1 protein allyl sulfide inhibits the reaction [Cyclophosphamide results in decreased expression of NOS1 protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of NOS1 protein] |
CTD |
PMID:31779506 PMID:35906875 |
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression increases activity decreases expression |
EXP ISO |
allyl sulfide inhibits the reaction [Cyclophosphamide results in decreased expression of NOS2 protein]; Bilirubin inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 mRNA]; Bilirubin inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; chrysin inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; ginkgolide B inhibits the reaction [Cyclophosphamide results in increased activity of NOS2 protein]; herbacetin inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Cyclophosphamide results in increased activity of NOS2 protein]; pimagedine inhibits the reaction [Cyclophosphamide results in increased activity of NOS2 protein]; rofecoxib inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; Rolipram inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 mRNA]; Rolipram inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; Rutin inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein] Cyclophosphamide results in increased expression of NOS2 mRNA; Cyclophosphamide results in increased expression of NOS2 protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein] |
CTD |
PMID:9006340 PMID:10607705 PMID:11046124 PMID:15821589 PMID:16879691 PMID:18206168 PMID:18296739 PMID:18710439 PMID:19691848 PMID:21068404 PMID:25753322 PMID:29753871 PMID:31779506 PMID:32197949 PMID:36198566 PMID:37263553 More...
|
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
decreases activity increases expression multiple interactions decreases expression |
EXP |
Cyclophosphamide results in decreased activity of NOS3 protein Cyclophosphamide results in increased expression of NOS3 protein Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in decreased expression of NOS3 protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in decreased expression of NOS3 protein] |
CTD |
PMID:9006340 PMID:16125470 PMID:35762198 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Notch1 |
notch receptor 1 |
multiple interactions decreases expression |
ISO |
PAX5 protein affects the reaction [Cyclophosphamide results in decreased expression of NOTCH1 protein]; SGI-1027 promotes the reaction [Cyclophosphamide results in decreased expression of NOTCH1 protein]; Valproic Acid inhibits the reaction [Cyclophosphamide results in decreased expression of NOTCH1 protein] |
CTD |
PMID:34658283 |
|
NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531
|
|
G |
Nppb |
natriuretic peptide B |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NPPB protein |
CTD |
PMID:17562616 PMID:18548196 PMID:18999883 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nprl2 |
NPR2-like, GATOR1 complex subunit |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of NPRL2 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 8:108,215,823...108,218,996
Ensembl chr 8:108,215,814...108,218,996
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
decreases expression multiple interactions increases expression |
EXP ISO |
Cyclophosphamide results in decreased expression of NQO1 mRNA; Cyclophosphamide results in decreased expression of NQO1 protein [astaxanthine co-treated with Cyclophosphamide] results in increased expression of NQO1 protein; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of NQO1 protein]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in decreased expression of NQO1 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in decreased expression of NQO1 protein] Cyclophosphamide results in increased expression of NQO1 mRNA Cyclophosphamide results in increased expression of NQO1 protein Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of NQO1 protein]; NFE2L2 gene mutant form inhibits the reaction [Cyclophosphamide results in increased expression of NQO1 mRNA]; NFE2L2 gene mutant form promotes the reaction [Cyclophosphamide results in decreased expression of NQO1 protein] |
CTD |
PMID:11906922 PMID:20038455 PMID:20433640 PMID:21041162 PMID:27633142 PMID:32197949 More...
|
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of NR1H4 mRNA |
CTD |
PMID:28391356 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity multiple interactions |
ISO |
Cyclophosphamide results in increased activity of NR1I2 protein [Cyclophosphamide results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 mRNA; [Cyclophosphamide results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; Cyclophosphamide binds to and results in increased activity of NR1I2 protein; NR1I2 protein promotes the reaction [Cyclophosphamide results in increased expression of ABCB1 protein] |
CTD |
PMID:17041008 PMID:18839173 PMID:20041327 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
[Cyclophosphamide results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA |
CTD |
PMID:17041008 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nr2c2 |
nuclear receptor subfamily 2, group C, member 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NR2C2 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 4:124,610,216...124,666,813
Ensembl chr 4:124,608,960...124,661,902
|
|
G |
Nrap |
nebulin-related anchoring protein |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NRAP mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 1:255,350,113...255,427,704
Ensembl chr 1:255,350,113...255,427,693
|
|
G |
Nrdc |
nardilysin convertase |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of NRDC mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 5:123,755,807...123,818,910
Ensembl chr 5:123,755,806...123,818,595
|
|
G |
Nrg1 |
neuregulin 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NRG1 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884
|
|
G |
Nrp1 |
neuropilin 1 |
decreases expression increases expression |
ISO EXP |
Cyclophosphamide results in decreased expression of NRP1 mRNA Cyclophosphamide results in increased expression of NRP1 mRNA |
CTD |
PMID:15331540 PMID:18632792 |
|
NCBI chr19:56,359,455...56,514,628
Ensembl chr19:56,359,455...56,513,633
|
|
G |
Nrp2 |
neuropilin 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NRP2 mRNA |
CTD |
PMID:18632792 |
|
NCBI chr 9:64,122,815...64,238,007
Ensembl chr 9:64,123,132...64,237,958
|
|
G |
Nt5c2 |
5'-nucleotidase, cytosolic II |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NT5C2 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 1:245,770,993...245,896,925
Ensembl chr 1:245,772,277...245,897,913
|
|
G |
Ntf3 |
neurotrophin 3 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NTF3 mRNA |
CTD |
PMID:10683293 |
|
NCBI chr 4:158,914,984...158,984,453
Ensembl chr 4:158,914,957...158,984,596
|
|
G |
Ntf4 |
neurotrophin 4 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NTF4 mRNA |
CTD |
PMID:10683293 |
|
NCBI chr 1:95,893,560...95,896,391
Ensembl chr 1:95,893,457...95,897,243
|
|
G |
Ntrk1 |
neurotrophic receptor tyrosine kinase 1 |
multiple interactions |
EXP |
Cyclophosphamide results in increased phosphorylation of and results in increased expression of NTRK1 protein |
CTD |
PMID:12412144 |
|
NCBI chr 2:173,236,961...173,253,806
Ensembl chr 2:173,236,963...173,253,770
|
|
G |
Ntrk2 |
neurotrophic receptor tyrosine kinase 2 |
multiple interactions |
EXP |
Cyclophosphamide results in increased phosphorylation of and results in increased expression of NTRK2 protein |
CTD |
PMID:12412144 |
|
NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136
|
|
G |
Nup42 |
nucleoporin 42 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NUP42 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 4:10,985,554...11,002,591
Ensembl chr 4:10,985,554...11,002,591
|
|
G |
Ocln |
occludin |
decreases expression multiple interactions increases expression |
ISO EXP |
Cyclophosphamide results in decreased expression of OCLN protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of OCLN protein] O-1602 compound inhibits the reaction [Cyclophosphamide results in increased expression of OCLN protein] |
CTD |
PMID:32151603 PMID:32615180 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of ODC1 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of OGG1 protein |
CTD |
PMID:27032448 |
|
NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766
|
|
G |
Opn3 |
opsin 3 |
affects response to substance |
ISO |
OPN3 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr13:87,589,333...87,619,847
Ensembl chr13:87,589,333...87,619,847
|
|
G |
Osm |
oncostatin M |
affects expression |
ISO |
Cyclophosphamide affects the expression of OSM mRNA |
CTD |
PMID:12624490 |
|
NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313
|
|
G |
P2rx3 |
purinergic receptor P2X 3 |
increases expression multiple interactions |
EXP |
Cyclophosphamide results in increased expression of P2RX3 protein GR 82334 inhibits the reaction [Cyclophosphamide results in increased expression of P2RX3 protein]; Suramin inhibits the reaction [Cyclophosphamide results in increased expression of P2RX3 protein] |
CTD |
PMID:23666265 |
|
NCBI chr 3:70,080,850...70,124,664
Ensembl chr 3:70,080,851...70,125,178
|
|
G |
P2ry2 |
purinergic receptor P2Y2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of P2RY2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 1:155,352,050...155,367,423
Ensembl chr 1:155,351,165...155,367,632
|
|
G |
Paip1 |
poly(A) binding protein interacting protein 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of PAIP1 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 2:51,523,190...51,550,241
Ensembl chr 2:51,522,921...51,550,241
|
|
G |
Pakap |
paralemmin A kinase anchor protein |
increases expression |
ISO |
Cyclophosphamide results in increased expression of PALM2AKAP2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 5:72,536,986...72,648,524 NCBI chr 5:72,313,646...72,450,645
Ensembl chr 5:72,181,718...72,648,524
|
|
G |
Pard3 |
par-3 family cell polarity regulator |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of PARD3 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr19:55,080,282...55,630,111
Ensembl chr19:55,080,282...55,629,778
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions decreases expression increases cleavage increases expression |
ISO EXP |
[Cladribine co-treated with Cyclophosphamide co-treated with Mitoxantrone] results in decreased expression of PARP1 protein; [Cladribine co-treated with Cyclophosphamide] results in decreased expression of PARP1 protein Cyclophosphamide results in decreased expression of PARP1 mRNA Cyclophosphamide results in increased cleavage of PARP1 protein Cyclophosphamide results in increased expression of PARP1 mRNA; Cyclophosphamide results in increased expression of PARP1 protein chrysin inhibits the reaction [Cyclophosphamide results in increased expression of PARP1 protein] |
CTD |
PMID:11599041 PMID:11723234 PMID:11906922 PMID:15582267 PMID:17898787 PMID:37263553 More...
|
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pax5 |
paired box 5 |
increases expression decreases methylation multiple interactions |
ISO |
Cyclophosphamide results in increased expression of PAX5 protein Cyclophosphamide results in decreased methylation of PAX5 gene Cyclophosphamide promotes the reaction [SGI-1027 results in increased expression of PAX5 protein]; PAX5 protein affects the reaction [Cyclophosphamide results in decreased expression of BCL2 protein]; PAX5 protein affects the reaction [Cyclophosphamide results in decreased expression of HES5 protein]; PAX5 protein affects the reaction [Cyclophosphamide results in decreased expression of JAG1 protein]; PAX5 protein affects the reaction [Cyclophosphamide results in decreased expression of NOTCH1 protein]; PAX5 protein affects the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein]; SGI-1027 promotes the reaction [Cyclophosphamide results in decreased methylation of PAX5 gene]; SGI-1027 promotes the reaction [Cyclophosphamide results in increased expression of PAX5 protein] |
CTD |
PMID:34658283 |
|
NCBI chr 5:58,763,334...58,945,719
Ensembl chr 5:58,765,036...58,944,326
|
|
G |
Pcna |
proliferating cell nuclear antigen |
affects expression increases expression decreases expression multiple interactions |
EXP ISO |
Cyclophosphamide affects the expression of PCNA mRNA Cyclophosphamide results in increased expression of PCNA mRNA Cyclophosphamide results in decreased expression of PCNA protein Cyclophosphamide results in decreased expression of PCNA mRNA coenzyme Q10 inhibits the reaction [Cyclophosphamide results in decreased expression of PCNA mRNA] |
CTD |
PMID:11056294 PMID:18246545 PMID:19701751 PMID:21041162 PMID:31557371 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pcsk2 |
proprotein convertase subtilisin/kexin type 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of PCSK2 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 3:130,880,422...131,183,127
Ensembl chr 3:130,880,422...131,183,127
|
|
G |
Pdcd4 |
programmed cell death 4 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of PDCD4 mRNA |
CTD |
PMID:21873647 |
|
NCBI chr 1:252,921,342...252,944,278
Ensembl chr 1:252,921,392...252,944,275
|
|
G |
Pdia3 |
protein disulfide isomerase family A, member 3 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of PDIA3 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 3:108,388,189...108,412,013
Ensembl chr 3:108,388,245...108,413,236
|
|
G |
Pdia4 |
protein disulfide isomerase family A, member 4 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of PDIA4 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr 4:76,803,198...76,822,245
Ensembl chr 4:76,803,198...76,822,107
|
|
G |
Pebp1 |
phosphatidylethanolamine binding protein 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of PEBP1 protein |
CTD |
PMID:15928459 |
|
NCBI chr12:39,302,864...39,307,064
Ensembl chr12:39,302,840...39,307,862
|
|
G |
Peli1 |
pellino E3 ubiquitin protein ligase 1 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of PELI1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr14:95,254,274...95,309,168
Ensembl chr14:95,254,589...95,308,285
|
|
G |
Per1 |
period circadian regulator 1 |
multiple interactions decreases expression |
ISO |
5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline inhibits the reaction [Cyclophosphamide results in decreased expression of PER1 mRNA] |
CTD |
PMID:30760223 |
|
NCBI chr10:53,800,126...53,814,963
Ensembl chr10:53,805,535...53,814,431
|
|
G |
Phlda2 |
pleckstrin homology-like domain, family A, member 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of PHLDA2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 1:198,696,897...198,699,292
Ensembl chr 1:198,696,897...198,697,836
|
|
G |
Piga |
phosphatidylinositol glycan anchor biosynthesis, class A |
increases mutagenesis |
EXP |
Cyclophosphamide results in increased mutagenesis of PIGA |
CTD |
PMID:22923490 |
|
NCBI chr X:30,043,033...30,055,861
Ensembl chr X:30,042,343...30,055,804
|
|
G |
Pigr |
polymeric immunoglobulin receptor |
increases expression |
ISO |
Cyclophosphamide results in increased expression of PIGR mRNA |
CTD |
PMID:15331540 |
|
NCBI chr13:42,298,905...42,326,877
Ensembl chr13:42,298,914...42,326,875
|
|
G |
Pla2g4a |
phospholipase A2 group 4A |
increases expression |
ISO |
Cyclophosphamide results in increased expression of PLA2G4A mRNA |
CTD |
PMID:21041162 |
|
NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Plau |
plasminogen activator, urokinase |
increases expression |
ISO |
Cyclophosphamide results in increased expression of PLAU mRNA |
CTD |
PMID:21527772 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Plod1 |
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of PLOD1 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 5:158,340,674...158,367,581
Ensembl chr 5:158,340,490...158,367,620
|
|
G |
Plod3 |
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of PLOD3 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr12:19,676,384...19,686,945
Ensembl chr12:19,676,386...19,686,960
|
|
G |
Pms1 |
PMS1 homolog 1, mismatch repair system component |
increases expression |
EXP |
Cyclophosphamide results in increased expression of PMS1 mRNA |
CTD |
PMID:11056294 |
|
NCBI chr 9:48,229,403...48,340,237
Ensembl chr 9:48,253,410...48,340,237
|
|
G |
Pms2 |
PMS1 homolog 2, mismatch repair system component |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of PMS2 mRNA |
CTD |
PMID:11056294 |
|
NCBI chr12:10,676,818...10,701,161
Ensembl chr12:10,676,764...10,701,066
|
|
G |
Polm |
DNA polymerase mu |
increases expression |
ISO |
Cyclophosphamide results in increased expression of POLM mRNA |
CTD |
PMID:20849824 |
|
NCBI chr14:80,707,075...80,716,677
Ensembl chr14:80,706,345...80,717,086
|
|
G |
Pomc |
proopiomelanocortin |
increases expression |
EXP |
Cyclophosphamide results in increased expression of POMC protein |
CTD |
PMID:15276878 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Pon1 |
paraoxonase 1 |
increases activity |
EXP |
Cyclophosphamide results in increased activity of PON1 protein |
CTD |
PMID:17874068 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions increases expression |
ISO EXP |
POR promotes the reaction [CYP2B6 results in increased susceptibility to Cyclophosphamide]; POR promotes the reaction [CYP2C18 results in increased susceptibility to Cyclophosphamide]; POR protein promotes the reaction [CYP2B6 protein results in increased susceptibility to Cyclophosphamide] Cyclophosphamide results in increased expression of POR mRNA |
CTD |
PMID:9766669 PMID:10919648 PMID:11599041 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Postn |
periostin |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of POSTN mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 2:138,527,714...138,559,098
Ensembl chr 2:138,527,696...138,559,099
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of PPARA protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of PPARA protein] |
CTD |
PMID:29753871 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression multiple interactions increases expression |
EXP |
Cyclophosphamide results in decreased expression of PPARG mRNA Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of PPARG mRNA] Cyclophosphamide results in increased expression of PPARG mRNA |
CTD |
PMID:25446862 PMID:27281708 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Prdm13 |
PR/SET domain 13 |
affects expression |
EXP |
Cyclophosphamide affects the expression of PRDM13 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 5:35,220,815...35,232,866
Ensembl chr 5:35,225,435...35,232,881
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
increases phosphorylation multiple interactions |
ISO |
Cyclophosphamide results in increased phosphorylation of PRKAA1 protein asperuloside promotes the reaction [Cyclophosphamide results in increased phosphorylation of PRKAA1 protein]; CSF2 protein promotes the reaction [Cyclophosphamide results in increased phosphorylation of PRKAA1 protein] |
CTD |
PMID:38348709 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkcg |
protein kinase C, gamma |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of PRKCG mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 1:65,832,851...65,860,676
Ensembl chr 1:65,832,855...65,859,384
|
|
G |
Prlr |
prolactin receptor |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of PRLR mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 2:59,134,147...59,324,719
Ensembl chr 2:59,134,588...59,324,718
|
|
G |
Procr |
protein C receptor |
increases expression |
ISO |
Cyclophosphamide results in increased expression of PROCR mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 3:144,254,596...144,258,863
Ensembl chr 3:144,254,380...144,258,903
|
|
G |
Prss3 |
serine protease 3 |
affects response to substance |
ISO |
PRSS3 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 4:70,203,088...70,206,562
Ensembl chr 4:70,203,088...70,206,562
|
|
G |
Prtn3 |
proteinase 3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of PRTN3 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 7:9,822,123...9,831,300
Ensembl chr 7:9,822,122...9,831,944
|
|
G |
Psma5 |
proteasome 20S subunit alpha 5 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of PSMA5 protein |
CTD |
PMID:17475930 |
|
NCBI chr 2:195,896,369...195,919,733
Ensembl chr 2:195,896,365...195,919,731
|
|
G |
Ptcra |
pre T-cell antigen receptor alpha |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of PTCRA mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 9:14,218,907...14,229,141
Ensembl chr 9:14,218,802...14,229,235
|
|
G |
Ptger1 |
prostaglandin E receptor 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of PTGER1 protein |
CTD |
PMID:20346049 |
|
NCBI chr19:24,470,258...24,473,687
Ensembl chr19:24,467,532...24,473,559
|
|
G |
Ptger4 |
prostaglandin E receptor 4 |
multiple interactions increases expression |
EXP |
Botulinum Toxins, Type A inhibits the reaction [Cyclophosphamide results in increased expression of PTGER4 protein] |
CTD |
PMID:18514386 PMID:20346049 |
|
NCBI chr 2:54,330,563...54,347,451
Ensembl chr 2:54,335,424...54,346,670
|
|
G |
Ptges3 |
prostaglandin E synthase 3 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of PTGES3 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr 7:490,698...507,759
Ensembl chr 7:490,656...508,084
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of PTGS1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
affects response to substance multiple interactions increases expression |
ISO EXP |
PTGS2 protein affects the susceptibility to Cyclophosphamide Botulinum Toxins, Type A inhibits the reaction [Cyclophosphamide results in increased expression of PTGS2 protein]; herbacetin inhibits the reaction [Cyclophosphamide results in increased expression of PTGS2 protein]; parthenolide inhibits the reaction [Cyclophosphamide results in increased expression of PTGS2 protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of PTGS2 mRNA]; Rutin inhibits the reaction [Cyclophosphamide results in increased expression of PTGS2 protein] Cyclophosphamide results in increased expression of PTGS2 mRNA; Cyclophosphamide results in increased expression of PTGS2 protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of PTGS2 protein] |
CTD |
PMID:12388444 PMID:15331540 PMID:16217747 PMID:17537839 PMID:18514386 PMID:19303104 PMID:25753322 PMID:29753871 PMID:36198566 PMID:37419146 More...
|
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptp4a1 |
protein tyrosine phosphatase 4A1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of PTP4A1 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 9:33,214,201...33,245,046
Ensembl chr 9:33,214,208...33,221,964
|
|
G |
Ptprc |
protein tyrosine phosphatase, receptor type, C |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of PTPRC mRNA |
CTD |
PMID:21041162 |
|
NCBI chr13:49,596,193...49,708,283
Ensembl chr13:49,596,193...49,708,692
|
|
G |
Pura |
purine rich element binding protein A |
increases expression |
EXP |
Cyclophosphamide results in increased expression of PURA mRNA |
CTD |
PMID:11599041 |
|
NCBI chr18:27,885,071...27,905,509
Ensembl chr18:27,884,556...27,905,513
|
|
G |
Rad50 |
RAD50 double strand break repair protein |
increases expression |
EXP |
Cyclophosphamide results in increased expression of RAD50 mRNA |
CTD |
PMID:11056294 |
|
NCBI chr10:37,809,353...37,861,309
Ensembl chr10:37,808,726...37,861,396
|
|
G |
Rad51 |
RAD51 recombinase |
decreases expression increases expression |
ISO EXP |
Cyclophosphamide results in decreased expression of RAD51 mRNA Cyclophosphamide results in increased expression of RAD51 mRNA |
CTD |
PMID:11599041 PMID:21041162 |
|
NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035
|
|
G |
Rad54l |
RAD54 like |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of RAD54L mRNA |
CTD |
PMID:11056294 |
|
NCBI chr 5:129,575,431...129,605,100
Ensembl chr 5:129,575,378...129,605,070
|
|
G |
Rag1 |
recombination activating 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of RAG1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 3:87,917,061...87,928,158
Ensembl chr 3:87,917,004...87,928,291
|
|
G |
Ramp1 |
receptor activity modifying protein 1 |
increases expression multiple interactions |
ISO |
Cyclophosphamide results in increased expression of RAMP1 mRNA RAMP1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 PMID:17403535 |
|
NCBI chr 9:91,765,481...91,816,152
Ensembl chr 9:91,781,285...91,816,151
|
|
G |
Rapsn |
receptor-associated protein of the synapse |
increases expression |
EXP |
Cyclophosphamide results in increased expression of RAPSN mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 3:77,015,073...77,024,378
Ensembl chr 3:76,983,471...77,024,373
|
|
G |
Rara |
retinoic acid receptor, alpha |
increases expression |
EXP |
Cyclophosphamide results in increased expression of RARA mRNA |
CTD |
PMID:16141653 |
|
NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
|
|
G |
Rarg |
retinoic acid receptor, gamma |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of RARG mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 7:133,367,833...133,390,301
Ensembl chr 7:133,367,833...133,390,177
|
|
G |
Rbpms |
RNA binding protein, mRNA processing factor |
increases expression |
ISO |
Cyclophosphamide results in increased expression of RBPMS mRNA |
CTD |
PMID:17403535 |
|
NCBI chr16:58,239,370...58,395,424
Ensembl chr16:58,239,474...58,395,426
|
|
G |
Rc3h1 |
ring finger and CCCH-type domains 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of RC3H1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr13:73,174,075...73,245,762
Ensembl chr13:73,173,946...73,238,839
|
|
G |
Rc3h2 |
ring finger and CCCH-type domains 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of RC3H2 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 3:21,121,531...21,186,711
Ensembl chr 3:21,110,679...21,179,933
|
|
G |
Reg3b |
regenerating family member 3 beta |
increases expression |
ISO EXP |
Cyclophosphamide results in increased expression of REG3A mRNA; Cyclophosphamide results in increased expression of REG3B mRNA Cyclophosphamide results in increased expression of REG3B protein |
CTD |
PMID:15331540 PMID:18295254 |
|
NCBI chr 4:110,861,775...110,865,015
Ensembl chr 4:110,861,775...110,865,015
|
|
G |
Reg3g |
regenerating family member 3 gamma |
increases expression |
ISO EXP |
Cyclophosphamide results in increased expression of REG3G mRNA Cyclophosphamide results in increased expression of REG3G protein |
CTD |
PMID:15331540 PMID:18295254 |
|
NCBI chr 4:110,922,805...110,927,803
Ensembl chr 4:110,924,168...110,926,723
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases expression multiple interactions increases activity increases phosphorylation |
EXP ISO |
Cyclophosphamide results in increased expression of RELA mRNA; Cyclophosphamide results in increased expression of RELA protein; Cyclophosphamide results in increased expression of RELA protein modified form Anthocyanins inhibits the reaction [Cyclophosphamide results in increased activity of RELA protein]; Melatonin inhibits the reaction [Cyclophosphamide results in increased expression of RELA protein]; parthenolide inhibits the reaction [Cyclophosphamide results in increased expression of RELA protein modified form]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased activity of RELA protein]; Quercetin inhibits the reaction [Cyclophosphamide results in increased expression of RELA mRNA]; sacubitril and valsartan sodium hydrate drug combination inhibits the reaction [Cyclophosphamide results in increased phosphorylation of RELA protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased phosphorylation of RELA protein] Cyclophosphamide results in increased localization of and results in increased activity of RELA protein; Dexamethasone inhibits the reaction [Cyclophosphamide results in increased localization of and results in increased activity of RELA protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased phosphorylation of RELA protein] |
CTD |
PMID:19303104 PMID:20433640 PMID:22099998 PMID:25451569 PMID:30506662 PMID:32197949 PMID:37419146 More...
|
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rev1 |
REV1, DNA directed polymerase |
decreases response to substance |
ISO |
REV1 protein results in decreased susceptibility to Cyclophosphamide |
CTD |
PMID:21068378 |
|
NCBI chr 9:40,278,100...40,351,764
Ensembl chr 9:40,278,101...40,351,576
|
|
G |
Ring1 |
ring finger protein 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of RING1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr20:4,830,120...4,833,623
Ensembl chr20:4,830,053...4,833,620
|
|
G |
Ripply3 |
ripply transcriptional repressor 3 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of RIPPLY3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr11:33,648,471...33,656,587
Ensembl chr11:33,648,486...33,656,584
|
|
G |
Rnase2 |
ribonuclease A family member 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of RNASE2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr15:24,449,618...24,450,427
Ensembl chr15:24,449,611...24,450,479
|
|
G |
Rnd1 |
Rho family GTPase 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of RND1 mRNA |
CTD |
PMID:23558518 |
|
NCBI chr 7:129,821,311...129,828,385
Ensembl chr 7:129,821,311...129,828,399
|
|
G |
Rnf138l1 |
ring finger protein 138 like 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of RNF138L1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr X:30,739,541...30,740,614
Ensembl chr X:30,739,413...30,740,613
|
|
G |
Rnf180 |
ring finger protein 180 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of RNF180 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 2:36,330,285...36,511,168
Ensembl chr 2:36,330,292...36,512,614
|
|
G |
Rnf216 |
ring finger protein 216 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of RNF216 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr12:11,454,752...11,576,305
Ensembl chr12:11,454,797...11,576,304
|
|
G |
Rnf44 |
ring finger protein 44 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of RNF44 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr17:9,919,982...9,934,376
Ensembl chr17:9,919,993...9,932,193
|
|
G |
Rnf5 |
ring finger protein 5 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of RNF5 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr20:4,145,539...4,147,985
Ensembl chr20:4,145,507...4,147,985
|
|
G |
Rorc |
RAR-related orphan receptor C |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of RORC protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of RORC protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of RORC protein] |
CTD |
PMID:32151603 |
|
NCBI chr 2:182,009,707...182,034,910
Ensembl chr 2:182,009,286...182,034,907
|
|
G |
Rpa1 |
replication protein A1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of RPA1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr10:60,148,869...60,199,970
Ensembl chr10:60,148,793...60,199,949
|
|
G |
Rpa2 |
replication protein A2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of RPA2 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 5:144,976,789...144,989,445
Ensembl chr 5:144,976,748...144,987,350
|
|
G |
Rps3 |
ribosomal protein S3 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of RPS3 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 1:153,778,363...153,783,663
Ensembl chr 1:153,777,472...153,783,680
|
|
G |
Rps6ka2 |
ribosomal protein S6 kinase A2 |
affects response to substance |
ISO |
RPS6KA2 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 1:52,631,582...52,906,739
Ensembl chr 1:52,631,736...52,906,739
|
|
G |
Rraga |
Ras-related GTP binding A |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of RRAGA mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 5:101,113,341...101,114,936
Ensembl chr 5:101,112,859...101,114,510
|
|
G |
Rras2 |
RAS related 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of RRAS2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 1:168,233,693...168,303,111
Ensembl chr 1:168,233,693...168,303,111
|
|
G |
Rrm1 |
ribonucleotide reductase catalytic subunit M1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of RRM1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:156,823,960...156,848,262
Ensembl chr 1:156,823,960...156,848,261
|
|
G |
Rrm2 |
ribonucleotide reductase regulatory subunit M2 |
multiple interactions |
ISO |
RRM2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773
|
|
G |
Rrm2b |
ribonucleotide reductase regulatory TP53 inducible subunit M2B |
increases expression |
ISO |
Cyclophosphamide metabolite results in increased expression of RRM2B mRNA |
CTD |
PMID:21704725 |
|
NCBI chr 7:69,077,024...69,108,742
Ensembl chr 7:69,078,291...69,108,633
|
|
G |
RT1-CE5 |
RT1 class I, locus CE5 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of HLA-F mRNA |
CTD |
PMID:20849824 |
|
NCBI chr20:3,403,418...3,479,476
|
|
G |
Rtel1 |
regulator of telomere elongation helicase 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of RTEL1 protein |
CTD |
PMID:17475930 |
|
NCBI chr 3:168,427,247...168,465,349
Ensembl chr 3:168,419,579...168,465,348
|
|
G |
Runx3 |
RUNX family transcription factor 3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of RUNX3 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 5:147,360,587...147,419,161
Ensembl chr 5:147,360,994...147,419,156
|
|
G |
Sall1 |
spalt-like transcription factor 1 |
affects response to substance |
ISO |
SALL1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr19:18,005,782...18,022,705
Ensembl chr19:18,007,503...18,022,705
|
|
G |
Satb1 |
SATB homeobox 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of SATB1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 9:4,677,817...4,773,061
Ensembl chr 9:4,680,920...4,753,251
|
|
G |
Scg3 |
secretogranin III |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of SCG3 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 8:76,399,777...76,442,015
Ensembl chr 8:76,399,777...76,442,015
|
|
G |
Scrt1 |
scratch family transcriptional repressor 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of SCRT1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 7:108,240,986...108,244,636
Ensembl chr 7:108,240,986...108,244,636
|
|
G |
Scube2 |
signal peptide, CUB domain and EGF like domain containing 2 |
multiple interactions |
ISO |
SCUBE2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 1:163,831,876...163,899,925
Ensembl chr 1:163,832,015...163,899,393
|
|
G |
Sec23a |
Sec23 homolog A, COPII coat complex component |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of SEC23A mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 6:76,658,793...76,706,125
Ensembl chr 6:76,658,427...76,706,035
|
|
G |
Serpine1 |
serpin family E member 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of SERPINE1 mRNA |
CTD |
PMID:23558518 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sesn2 |
sestrin 2 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of SESN2 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260
|
|
G |
Sfn |
stratifin |
increases expression |
ISO |
Cyclophosphamide results in increased expression of SFN mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314
|
|
G |
Sgce |
sarcoglycan, epsilon |
affects response to substance |
ISO |
SGCE protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 4:32,771,477...32,842,238
Ensembl chr 4:32,771,477...32,842,254
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of SGK1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 1:22,980,257...23,098,122
Ensembl chr 1:22,980,261...23,098,283
|
|
G |
Sharpin |
SHANK-associated RH domain interactor |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of SHARPIN mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 7:108,070,681...108,075,012
Ensembl chr 7:108,070,687...108,074,955
|
|
G |
Sirt3 |
sirtuin 3 |
increases expression multiple interactions |
ISO |
Cyclophosphamide results in increased expression of SIRT3 mRNA Carnitine inhibits the reaction [Cyclophosphamide results in increased expression of SIRT3 mRNA] |
CTD |
PMID:37863343 |
|
NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808
|
|
G |
Sirt5 |
sirtuin 5 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of SIRT5 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr17:21,310,028...21,337,137
Ensembl chr17:21,310,028...21,337,101
|
|
G |
Sit1 |
signaling threshold regulating transmembrane adaptor 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of SIT1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 5:57,740,212...57,741,838
Ensembl chr 5:57,740,218...57,741,838
|
|
G |
Slc18a3 |
solute carrier family 18 member A3 |
increases expression multiple interactions |
EXP |
Cyclophosphamide results in increased expression of SLC18A3 protein O-1602 compound inhibits the reaction [Cyclophosphamide results in increased expression of SLC18A3 protein] |
CTD |
PMID:32615180 |
|
NCBI chr16:7,713,630...7,716,491
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
increases expression multiple interactions |
EXP |
Cyclophosphamide results in increased expression of SLC22A3 protein O-1602 compound inhibits the reaction [Cyclophosphamide results in increased expression of SLC22A3 protein] |
CTD |
PMID:32615180 |
|
NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
multiple interactions decreases expression |
EXP |
Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 mRNA]; Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 protein] Cyclophosphamide results in decreased expression of SLC22A5 mRNA; Cyclophosphamide results in decreased expression of SLC22A5 protein |
CTD |
PMID:22701146 |
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of SLC2A2 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933
|
|
G |
Slc2a6 |
solute carrier family 2 member 6 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of SLC2A6 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 3:10,348,395...10,355,208
Ensembl chr 3:10,348,395...10,355,208
|
|
G |
Slc39a13 |
solute carrier family 39 member 13 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of SLC39A13 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 3:77,039,411...77,047,528
Ensembl chr 3:77,037,565...77,049,226
|
|
G |
Slc39a14 |
solute carrier family 39 member 14 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of SLC39A14 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr15:45,376,806...45,423,549
Ensembl chr15:45,376,917...45,423,524
|
|
G |
Slc39a5 |
solute carrier family 39 member 5 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of SLC39A5 mRNA; Cyclophosphamide results in increased expression of SLC39A5 protein |
CTD |
PMID:27281708 |
|
NCBI chr 7:822,873...830,865
Ensembl chr 7:824,818...830,242
|
|
G |
Slc39a6 |
solute carrier family 39 member 6 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of SLC39A6 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr18:15,864,874...15,885,417
Ensembl chr18:15,864,875...15,885,417
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of SLC3A2 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931
|
|
G |
Slc40a1 |
solute carrier family 40 member 1 |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of SLC40A1 protein Dexrazoxane inhibits the reaction [Cyclophosphamide results in decreased expression of SLC40A1 protein] |
CTD |
PMID:37690746 |
|
NCBI chr 9:48,033,526...48,053,876
Ensembl chr 9:48,033,526...48,051,481
|
|
G |
Slc43a1 |
solute carrier family 43 member 1 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of SLC43A1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 3:69,920,586...69,946,768
Ensembl chr 3:69,920,649...69,946,768
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
affects expression decreases expression multiple interactions |
ISO |
Cyclophosphamide affects the expression of SLC7A11 mRNA Cyclophosphamide metabolite results in decreased expression of SLC7A11 mRNA Cyclophosphamide results in decreased expression of SLC7A11 protein Dexrazoxane inhibits the reaction [Cyclophosphamide results in decreased expression of SLC7A11 protein] |
CTD |
PMID:23824090 PMID:24356939 PMID:37690746 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Slfn4 |
schlafen family member 4 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of SLFN4 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr10:67,994,601...68,018,141
Ensembl chr10:68,000,028...68,018,138 Ensembl chr10:68,000,028...68,018,138
|
|
G |
Slit1 |
slit guidance ligand 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of SLIT1 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 1:240,409,559...240,558,127
Ensembl chr 1:240,409,561...240,558,127
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of SLPI mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453
|
|
G |
Snx10 |
sorting nexin 10 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of SNX10 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 4:80,612,648...80,677,005
Ensembl chr 4:80,612,669...80,676,996
|
|
G |
Soat1 |
sterol O-acyltransferase 1 |
affects response to substance |
ISO |
SOAT1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr13:68,552,274...68,597,529
Ensembl chr13:68,552,317...68,597,494
|
|
G |
|